TW527195B - Fast-soluble solid pharmaceutical combinations - Google Patents
Fast-soluble solid pharmaceutical combinations Download PDFInfo
- Publication number
- TW527195B TW527195B TW087116540A TW87116540A TW527195B TW 527195 B TW527195 B TW 527195B TW 087116540 A TW087116540 A TW 087116540A TW 87116540 A TW87116540 A TW 87116540A TW 527195 B TW527195 B TW 527195B
- Authority
- TW
- Taiwan
- Prior art keywords
- grams
- water
- pharmaceutical composition
- weight
- solubility
- Prior art date
Links
- 239000007787 solid Substances 0.000 title claims abstract description 97
- 239000003814 drug Substances 0.000 claims abstract description 99
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 87
- 229940079593 drug Drugs 0.000 claims abstract description 84
- 235000000346 sugar Nutrition 0.000 claims abstract description 47
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 150000008163 sugars Chemical class 0.000 claims abstract description 23
- 239000007864 aqueous solution Substances 0.000 claims abstract description 17
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 13
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 238000011049 filling Methods 0.000 claims description 25
- 150000001720 carbohydrates Chemical class 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 15
- 229930006000 Sucrose Natural products 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- 239000005720 sucrose Substances 0.000 claims description 15
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 14
- 239000004375 Dextrin Substances 0.000 claims description 14
- 229920001353 Dextrin Polymers 0.000 claims description 14
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 14
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 14
- 235000019425 dextrin Nutrition 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 10
- -1 xylose Sugar alcohol Chemical class 0.000 claims description 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 8
- 239000004386 Erythritol Substances 0.000 claims description 8
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 8
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 8
- 235000019414 erythritol Nutrition 0.000 claims description 8
- 229940009714 erythritol Drugs 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 235000010356 sorbitol Nutrition 0.000 claims description 8
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 239000002270 dispersing agent Substances 0.000 claims description 6
- 239000005715 Fructose Substances 0.000 claims description 5
- 229930091371 Fructose Natural products 0.000 claims description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 5
- 229920002907 Guar gum Polymers 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 235000010417 guar gum Nutrition 0.000 claims description 5
- 239000000665 guar gum Substances 0.000 claims description 5
- 229960002154 guar gum Drugs 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 229920000945 Amylopectin Polymers 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 150000004804 polysaccharides Chemical class 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 claims description 3
- 239000001904 Arabinogalactan Substances 0.000 claims description 3
- 229920000189 Arabinogalactan Polymers 0.000 claims description 3
- 235000009467 Carica papaya Nutrition 0.000 claims description 3
- 240000006432 Carica papaya Species 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229920000161 Locust bean gum Polymers 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 240000004584 Tamarindus indica Species 0.000 claims description 3
- 235000004298 Tamarindus indica Nutrition 0.000 claims description 3
- 229920001615 Tragacanth Polymers 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 235000019312 arabinogalactan Nutrition 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 235000010420 locust bean gum Nutrition 0.000 claims description 3
- 239000000711 locust bean gum Substances 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 229920001059 synthetic polymer Polymers 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- 240000004731 Acer pseudoplatanus Species 0.000 claims description 2
- 235000002754 Acer pseudoplatanus Nutrition 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 235000006485 Platanus occidentalis Nutrition 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 229920005615 natural polymer Polymers 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000004698 Polyethylene Substances 0.000 claims 1
- 239000000305 astragalus gummifer gum Substances 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 235000001727 glucose Nutrition 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 235000015424 sodium Nutrition 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 115
- 210000000214 mouth Anatomy 0.000 abstract description 25
- 239000000725 suspension Substances 0.000 description 51
- 239000000243 solution Substances 0.000 description 28
- 238000004090 dissolution Methods 0.000 description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 239000011812 mixed powder Substances 0.000 description 13
- 239000008213 purified water Substances 0.000 description 13
- 108010011485 Aspartame Proteins 0.000 description 12
- 239000000605 aspartame Substances 0.000 description 12
- 235000010357 aspartame Nutrition 0.000 description 12
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 12
- 229960003438 aspartame Drugs 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 230000033228 biological regulation Effects 0.000 description 11
- 230000002079 cooperative effect Effects 0.000 description 10
- 235000013599 spices Nutrition 0.000 description 10
- 229920002261 Corn starch Polymers 0.000 description 9
- 239000008120 corn starch Substances 0.000 description 9
- 238000004108 freeze drying Methods 0.000 description 8
- 239000002689 soil Substances 0.000 description 8
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000007937 lozenge Substances 0.000 description 7
- 238000002483 medication Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 229920000591 gum Polymers 0.000 description 6
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 238000009423 ventilation Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 238000007639 printing Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 3
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 240000008415 Lactuca sativa Species 0.000 description 2
- 235000003228 Lactuca sativa Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 240000000111 Saccharum officinarum Species 0.000 description 2
- 235000007201 Saccharum officinarum Nutrition 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 210000000467 autonomic pathway Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 239000006104 solid solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- NRGGMCIBEHEAIL-UHFFFAOYSA-N 2-ethylpyridine Chemical compound CCC1=CC=CC=N1 NRGGMCIBEHEAIL-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- RXUORJSZMBEMGC-UHFFFAOYSA-N C(C=C/C(=O)O)(=O)O.NC1=CC=CC=C1 Chemical compound C(C=C/C(=O)O)(=O)O.NC1=CC=CC=C1 RXUORJSZMBEMGC-UHFFFAOYSA-N 0.000 description 1
- 101100537629 Caenorhabditis elegans top-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 244000260524 Chrysanthemum balsamita Species 0.000 description 1
- 235000005633 Chrysanthemum balsamita Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013642 Drooling Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241000519695 Ilex integra Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- IKMPWMZBZSAONZ-UHFFFAOYSA-N Quazepam Chemical compound FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12 IKMPWMZBZSAONZ-UHFFFAOYSA-N 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 101150107801 Top2a gene Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- KPQJOKRSYYJJEL-VLQRKCJKSA-K [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O Chemical compound [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O KPQJOKRSYYJJEL-VLQRKCJKSA-K 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003576 central nervous system agent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003189 isokinetic effect Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940018415 meclizine hydrochloride Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229960000293 pirenzepine hydrochloride Drugs 0.000 description 1
- FFNMBRCFFADNAO-UHFFFAOYSA-N pirenzepine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 FFNMBRCFFADNAO-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229960001964 quazepam Drugs 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- CCXAYLQLOLXXKE-DWJAGBRCSA-K trisodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-t Chemical compound [Na+].[Na+].[Na+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C([O-])=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O CCXAYLQLOLXXKE-DWJAGBRCSA-K 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
527195 經滴部中央標準局員工消費合作社印製 A7 五、發明説明(,) 技術領域 本發明為醑於速溶性固形製劑、詳細而言,為關於在 口腔等之水分有限的愛用場所、迅速地崩隳、溶解之速 溶性固形製劑。 背景技術 以往,為了藥劑呑嚥困難之患者,高齡者或兒童,乃 進行易服用製劑型式之於口腔内急速地崩壤、溶解之固 形製劑的開發。例如,於持開昭53-446 19、持開昭58-113121、特開平3-56412、持開平3-86837、待表平9-502622各公報中,乃提案使用冷凍乾燥技術固形製劑。 又,於特開平2-32014或特開平5-271054中,提案採用 令濕潤之製劑粉末於低壓中加壓成型後,乾燥所得之濕 製綻劑之固形製劑。 更且,於特開昭58- 1 94808、持表平6-502 1 94、特開 平5-310558、特開平8-99904、特開平8-208520、特開 平8-208521、特開平8-333243、特開平9-71523之各公 報中,提案採用壓縮成形之於口腔内溶解、崩壤之固形 製劑。又,於W0 93/12769中,提案經由令藥物與乳糖 和/或甘露糖醇之混合粉末於洋菜水溶液中分散、並且 充填於模板後,乾燥而取得之固形製劑。 但是,上述所提案之先前的各種製劑,於製劑學上仍 未能稱為充分,為含有各種問題點。例如,於進行加壓 成型之製造方法中,不僅根據通常之壓縮成型,卽使以 濕製錠劑之製法亦可能提高硬度,但經由此方法所取得 本紙張尺度適用中國國家標準(CNS ) Λ4規枱(210X 297公f ) „—^—1^—4^水------、訂----- (讀先閱讀背面之注意事項再填寫本頁) 527195 A7 Η 7 五、發明説明( > 有損 ,亦 者時 再解 C溶 長内 變腔 間口 時於 壞, 崩劑 、壤 解崩 溶之 之性 内溶 腔不 口水 於加 多添 ,須 劑必 製亦 之時 性易 時有 經具 起亦 引且 易更 者 , 物性 然定 天 菜 洋物 和藥 膠合 明 組 用及 使損 ,亦 又且 ο » 感等 用色 服變 及地 安 之 之 大 率 隙 空 為 傺 因 劑 製 之 法 燥 乾 .C ο 搏 點冷 缺用 之使 等 , 薗地 雜對 殖相 繁 身硬 本之 劑劑 0 0 因因 但 , ,者 速再 迅, 常量 非含 為之 性物 解藥 溶高 之提 内以 腔 0 口般 於一 故故 劑鬆 afl-3ttflo 作之 操度 和濕 管高 保溫 劑高 製於 之 , 常地 日別易 於特而 • 〇 質難 物困 之之 壤等 易強 且 性 脆濕 為吸 故有 ,具 低多 度上 或之 ,劑 化製 變於 狀之 形等 劑上 製指 令手 於 附 濕粘 吸亦 由劑 經製 , 住 中抓 所僅 場時 之用 件服 條於 候使 氣即 操發 礙 障 成 造 亦 上 作 (謂先閱讀背面之注意事項再填寫本頁 訂 崩 地固 速性 迅溶 等速 内之 腔度 口硬 於之 ,用 點實 題耐 問可 述有 上具 決併 解兼 供且 提並 以 , 示為解 掲明溶 之發 、 明本壞 的 巨 為 法 製 A3 其 及 f 劑 0 形 經漓部中央標準局員工消費合作社印製 達與 了 、 為物 藥 令 由 經 供 提 為 態 形 1 第 之 明 發 本 的 巨 類 此 成 類 糖 之 下 以 克 ο 3 為 度 解 溶 之 克 ο ο 1 水 對 下 溫 室 室溶 於金 ,完 類不 耱為 之類 上糖 以之 克下 30以 為克 度30 解為 溶度 之解 克溶 00之 對10 下水 溫對 室下 及溫 製 形 固 性 溶 之 得 取 所 分 水 去 除 後 合 0 中 水 之 量 份。 解劑 聚 及 類 糖 f 物 藥 令 由 經 供 提 為 I 態 4 形· 二 第 之 明 發 本 又 本紙張尺度適用中國國家標準(CNS ) Λ4規枱(210Χ297^^ ) 527195 A7 B7 五、發明説明(4 溶 之固 機 類性 有 糖溶 去 於速 除 物之 , 藥得 後 令取 散 由所 分 經燥 、 供乾 解 提凍 溶。為冷 中劑態、 劑製形散 溶形三分 機固第或 有性之 \ 於溶明和 酮速發解 烷之本溶 咯得 ,中 吡取且解 烯所更溶 乙爾 水 製溶 形中 固等 性劑 溶溶 速機 之有 態或 形液 三溶 第水 至於 態 , 形類 1 糖 態第與 形之物 佳供藥 最提用 之所使 。明明有 _ 發發具 製施本為 形實 _ 乾 速 物 之 成 中 組 C 態 浮 _ 形 懸製三 類形第 此固至 令性態 且溶形 並速一 ,之第 物欲些 成所此 組得明 浮取說 懸此細 成藉詳。 作,別劑 、徽値製 散特,形 分其下固 、為以性 解燥 溶 (讀先閱讀背面之注意事項再填寫本頁 衣·527195 Printed by the Consumer Standards Cooperative of the Central Bureau of Standards Department A7 V. Description of the Invention (,) Technical Field The present invention is a fast-dissolving solid preparation, in particular, it is a favorite place for limited use of water in the oral cavity, etc., quickly. Collapse and dissolve fast soluble solid preparation. Background Art In the past, for patients who have difficulty in swallowing medicines, elderly people, or children, the development of a solid preparation that rapidly collapses and dissolves in the oral cavity in the form of an easy-to-take preparation has been developed. For example, in the respective publications of Chikai Kai 53-446 19, Chikai Kai 58-113121, Japanese Patent Laid-Open No. 3-56412, Chikai Kaihei 3-86837, and Tobei Hei 9-502622, it is proposed to use a freeze-dried solid preparation. In addition, in JP-A-Heisei 2-32014 or JP-A-Heisei 5-271054, it is proposed to use a solid preparation of a wet fragrant obtained by press-molding a wet preparation powder under low pressure and drying. Moreover, Yukai Sho 58- 1 94808, Hiroki Hei 6-502 1 94, JP-A 5-310558, JP-A 8-99904, JP-A 8-208520, JP-A 8-208521, JP-A 8-333243 In each of JP-A-9-71523, it is proposed to use a compression-molded solid preparation that dissolves and collapses in the oral cavity. Also, in WO 93/12769, a solid preparation obtained by dispersing a mixed powder of a drug with lactose and / or mannitol in an aqueous solution of agaric, filling it with a template, and then drying it is proposed. However, the previous formulations proposed above have not been described as sufficient in terms of formulation, and they contain various problems. For example, in the manufacturing method of pressure molding, not only the usual compression molding, but also the method of making wet tablets can also increase the hardness, but the paper size obtained through this method applies the Chinese National Standard (CNS) Λ4 Regulations (210X 297 male f) „— ^ — 1 ^ —4 ^ Water ------, order ----- (Read the precautions on the back before filling this page) 527195 A7 Η 7 V. Explanation of the invention (> Loss, or when the solution is dissolved, the internal cavity will change and the cavity will be broken, and the disintegrating agent, soil disintegrate and dissolve, the internal cavity will not be drooling, and the agent must be prepared. Time is easy to change, and it is easy to change, and it is easy to change and change. The physical properties are fixed and used for damage, and also »» The color rate change and the large rate gap of ground security. The empty is the method of making the agent dry. C ο Blow the cold and use it, etc., the agent of the complex to the colony phase is a hard agent 0 0 because of the,, the speed is faster, the constant is not included For the purpose of sexual dissolution, the solution is highly soluble, and the cavity is 0 mouths in the same way as the reason agent pine afl-3ttflo. The operating temperature and wet pipe high heat preservation agent are highly controlled. It is easy to be special in the ordinary place. 〇 The soil with high quality and difficult materials is easy to be brittle and wet. It is absorbing, so it has a low degree. The system changes to the shape of the agent, etc. The instructions on the preparation of the hand with wet sticking are also made by the agent, and the piece of service is only used when the residence is in the field. First read the notes on the back and then fill out this page to fix the cavity in the fast-fixing and fast-solving isokinetic mouth. Use the point to answer the question, you can provide the final solution, and provide the solution. It is shown as a solution to the problem of dissolving and dissolving, and the bad and bad is the legal system A3, and f agent 0. It is printed by the Ministry of Standards Bureau employee consumer cooperatives, and the order for the medicine is changed from the supply to the state. The mega class of Mingfa Ben is a gram of sugar that is dissolved under the degree of ο 3 as the degree of dissolution. Ο 1 Water is dissolved in gold in the lower greenhouse, and the type of sugar is 30 grams per gram. The solution of 30 is the solution of solubility, and the solution of 00 is 10 The water temperature can be obtained from the solid solution under the room and the warm shape. After the water is removed, the amount of water in the water is 0. The polysaccharide and the sugar-like substance are ordered from the supply to the I state. Zhimingfa and this paper are in accordance with Chinese National Standards (CNS) Λ4 gauge (210 × 297 ^^) 527195 A7 B7 V. Description of the invention (4 The solid machine is soluble in sugar. After the order is taken out, the separated powders are dried and thawed for drying and thawing. It is solid in the cold state, and it is made in the form of a solid solution. The three-part machine can be solid or insoluble. In the solution of Rongming and ketone, the solvent can be quickly dissolved. The solid-state isotropic agent dissolves in the dissolving speed machine, or the liquid-three-soluble water is in the state, and the form 1 is the sugar state and the shape of the substance is best used for medicine. It is clear that _ the hair and hair tools are made in shape and form _ dry speed matter into the middle group C state floating _ shape suspension three types of shape are fixed to make the character and dissolve and speed one, the first thing wants some accomplishment This group has to make a clear statement. As a special agent, a special agent made by Huizhang, it is a solid form, and it is used to dissolve dryness. (Read the precautions on the back before filling in this page.
、1T 本發明所提供之第一形態中之速溶性固形製劑,其態 樣之一為經由令藥物,與室溫下對水100克之溶解度為 30克以下之耱類及室溫下對水100克之溶解度為30克以 上之耱類,於室溫下對水100克之溶解度為30克以下之 糖類為不完全溶解份量之水中混合後,除去水分所得之 速溶性固形製劑。 此類速溶性固形製劑具體而言,為經由令藥物,與室 溫下對水100克之溶解度為30克以下之糖類及室溫下對 水100克之溶解度為30克以上之糖類,於室溫下對100克 水之溶解度為30克以下之糖類為不完全溶解份量之水中 混合,取得乳狀懸浮液,其次將此懸浮液充填至製劑用 模板後,除去水分而製造。 本紙張尺度適用中國國家標準(CNS)A4規枱(210X297公f ) % 經漓部中央標準局員工消費合作社印製 527195 經滴部中央標率局員工消費合作社印製 A7 B7 五、發明説明(4 ) 卽,本發明所提供之第一之速溶性固形製劑為具有對 於藥物,組合使用對於水之溶解性低之糖類,及對於水 之溶解性高之糖類兩者,作成水条懸浮液之乳狀組成物 後,除去水分為其特激。 若根據本發明者等之檢討,將藥物僅與對水溶解性低 之糖類組合,則所得之懸浮液不能成為所欲的乳狀組成 物,於充镇時則産生藥物和糖類與水分之分離,並且無 法均勻充填。再者,將此組成物乾燥後之固形製劑其表 面産生凹凸,缺乏作為實際製劑之實用性。 B—方面,將藥物僅與對水溶解性高之糖類組合之組 成物則因為呈水溶液型式之組成物,於室溫送風和減壓 乾燥下並無法充分乾燥成固形製劑化,或者即使可將其 乾燥,亦需要許多時間,缺乏生産性。 但是,令人驚訝地,發現對於藥物,將對於水之溶解 性低之耱類與對於水之溶解性高之糖類兩者組合作成水 条懸浮物之乳狀組成物,並且將此組成物於常溫下通風 乾燥、或減壓乾燥除去水分所得之固形製劑,為具有可 耐實用之硬度,並且即使不與水共同服用亦可在口腔内 等中迅速崩壤、溶解,更且不霈要煩雜之製造工程,且 視需要可提高藥物之含量。 於本發明所提供之形態中,速溶性固形製劑中所使用 之對於水之溶解性低之糖類為溶解於大量水中,但不溶 解於少量水中之糖類,即於室溫下對於水100克之溶解 度為30克以下之糖類。只要具有此類溶解度,則對於此 (請先閲讀背面之注意事項再填寫本頁) 衣.1T The fast-dissolving solid preparation in the first form provided by the present invention, one of the aspects is that the drug has a solubility with 100 g of water at room temperature and a solubility of 30 g or less at room temperature and 100 with water at room temperature. An instant soluble solid preparation obtained by mixing water having a solubility of 30 grams or more and 100 grams of water having a solubility of 30 grams or less in water at room temperature as an incompletely dissolved amount of water and removing water. Specifically, such fast-dissolving solid preparations are prepared by adjusting the drug to 100 g of water with a solubility of 30 g or less in water at room temperature and 100 g of water with a solubility of 30 g or more to water at room temperature. The saccharides having a solubility of 30 g or less in 100 g of water are mixed with water having an incompletely dissolving amount to obtain a milky suspension, and the suspension is then filled into a template for a preparation and then manufactured by removing water. This paper size applies to Chinese National Standard (CNS) A4 regulations (210X297 male f)% Printed by the Consumers 'Cooperative of the Central Standards Bureau of the Ministry of Printing 527195 Printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Printing A7 B7 V. Description of the invention ( 4) Alas, the first fast-dissolving solid preparation provided by the present invention is a combination of saccharides with low solubility in water for drugs, and saccharides with high solubility in water, used as a water strip suspension. After the milky composition, the moisture is removed to make it special. According to the review by the inventors, if the drug is only combined with sugars with low water solubility, the resulting suspension cannot become the desired milky composition, and the drug and sugar are separated from water when filling And cannot be filled evenly. Furthermore, the surface of the solid preparation after drying the composition has unevenness, and it lacks practicality as an actual preparation. B—On the other hand, the composition that combines the drug with only water-soluble sugars is a composition in the form of an aqueous solution, and it cannot be dried into a solid preparation under room temperature air supply and reduced pressure drying. It also takes a lot of time to dry and lacks productivity. Surprisingly, however, it was found that for medicines, a combination of tadpoles with low solubility in water and sugars with high solubility in water was combined to form a milky composition of a water strip suspension, and this composition was used in The solid preparation obtained by ventilating and drying at room temperature or removing moisture under reduced pressure has a hardness that is resistant to practical use, and can quickly collapse and dissolve in the oral cavity and the like without taking it with water. Manufacturing process, and if necessary, the content of the drug can be increased. In the form provided by the present invention, the saccharides having low solubility in water used in the instant solid preparations are saccharides that are soluble in a large amount of water but not in a small amount of water, that is, a solubility of 100 grams of water at room temperature. For sugars below 30 grams. As long as you have such solubility, please read this (please read the notes on the back before filling this page).
I準 標 家 國 國 I中 用 適 度 尺 張 紙I quasi-standard home country I use moderate rule paper
Ns 527195 經濟部中央標準局負工消費合作社印製 A7 五、發明説明(,) 耱類之種類並無特別限定,具體而言可列舉乳耱,甘露 糖醇等,其可單獨或混合二種以上供使用。 又,對於水之溶解性高之糖類為室溫下,對於水100 克之溶解度為30克以上之糖類,只要具有此類溶解度, _對於此糖類之種類並無特別限定。此類糖類之具體例 可列舉果糖、葡萄糖、蔗糖、木糖、海藻糖、木糖醇、 山梨糖醇、赤蘚糖醇、糊精、支鐽澱粉等。此些糖類可 單獨或亦可混合二種以上供使用。又,亦可以粉末型式 使用,且亦可再溶解於水中作成水溶液狀態後,添加至 藥物與對水溶解性低之糖類之混合粉末中亦可。 本發明中,與藥物配合、使用之上述對於水之溶解性 低之糖類與對於水之溶解性高之糖類之混合比率,若根 據本發明者等之檢紂,則判定固形成分之重量比為在95 :2〜80: 20之範圍内,為較佳保持迅速之崩壤、溶解性 持性,並且於製造時可在較短時間下進行乾燥。 再者,本發明中,與藥物共同使用之對於水之溶解性 低之糖類與對於水之溶解性高之糖類兩者,於製劑中之 配合量為依據所使用藥物之性質、和共同配合之添加物 而變化。但是,為了保持可霈實用之硬度和迅速的溶解 性,一般上,固形製劑之全部固形成分較佳為配合40重 量%以上,再佳為60重量%以上。 另一方面,本發明固形製劑中所含之藥物含量雖亦為 根據每一服用之服用量、和藥物之物化性質,但以全部 固形成分之60重量%以下為較佳,且再佳為全部固形成 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210'乂297公犛) ---·--1^---衣------訂----- (讀先閱讀背面之注意事項再填寫本頁) 527195 經滴部中央標準局貝工消費合作社印製 A7 1Π 五、發明説明(k ) 分之40重量%以下。 而且,於本發明所提供之第一形態中,速溶性固形製 劑之較佳的具體態樣為將全部固形成分之60重量%以下 、較佳為40重量%以下之藥物,與室溫下對於水100克 之溶解度為30克以下之糖類及室溫下對於水100克之溶 解度為30克以上之糖類,以固形成分重量比98 : 2〜80 :20,並使用全部固形成分之40重量%以上、較佳為60 重量%以上,與室溫下對水100克之溶解度為30克以下之 糖類為不完全溶解份量之水混合後,除去水分所取得之 速溶性固形製劑。 本發明第一形態中之速溶性固形製劑之大小及形狀之 製劑形態並無特別限定。例如,可作成通常之製劑形態 之粒劑、丸劑、錠劑、栓劑等,其中亦以作成錠_為佳。 此類速溶性固形製劑之製造方法具體而言可如下進行 。即,於藥物、對於水之溶解性低之糖類及對於水之溶 解性高之糖類混合之混合粉末中,添加精製水,作成乳 狀懸浮液後,將此懸浮液充填至所欲之製劑模板,例如 凹型模板之穴中、乾燥則可取得目的之固形製劑。 尚,藥物及對水之溶解性高之糖類兩者之混合亦可於 精製水中溶解添加。 又,由懸浮液中除去水分之乾燥,可在常溫下通風乾 燥或以減壓乾燥進行。 依據此類製法所製造之具有第一形態之本發明的速溶 性固形製劑,並未特別採用加壓成型和冷凍乾燥等之工 -8 - 本紙張尺度適用中國國家標準(CNS ) Λ4規掊(210X297公餘) (請先閱讀背面之注意事項再填寫本頁)Ns 527195 Printed by A7 Consumers' Cooperative of Central Standards Bureau of the Ministry of Economic Affairs 5. Description of Invention (,) The type of 耱 is not particularly limited. Specific examples include milk 耱, mannitol, etc., which can be used alone or in combination. The above is for use. In addition, for sugars having high solubility in water, at room temperature, and sugars having a solubility of 30 grams or more for 100 grams of water, as long as such sugars have such solubility, the type of the sugar is not particularly limited. Specific examples of such sugars include fructose, glucose, sucrose, xylose, trehalose, xylitol, sorbitol, erythritol, dextrin, and branched starch. These sugars may be used singly or in combination of two or more kinds. It can also be used in powder form, or it can be redissolved in water to form an aqueous solution, and it can also be added to a mixed powder of drugs and sugars with low water solubility. In the present invention, the mixing ratio of the above-mentioned low-water-soluble sugars with high-water-soluble sugars used in combination with drugs is determined by the inventors and others to determine the weight ratio of solids as In the range of 95: 2 ~ 80: 20, it is better to maintain rapid soil collapse and solubility, and it can be dried in a short time during manufacture. Furthermore, in the present invention, the amount of saccharides with low solubility in water and saccharides with high solubility in water used together with drugs in the formulation is based on the properties of the drugs used and the combined Additives vary. However, in order to maintain practical hardness and rapid solubility, in general, the total solid content of the solid preparation is preferably 40% by weight or more, and more preferably 60% by weight or more. On the other hand, although the content of the drug contained in the solid preparation of the present invention is also based on the amount of each dose taken and the physicochemical properties of the drug, it is preferably 60% by weight or less of the total solid content, and even more preferably all The solid paper size is applicable to the Chinese National Standard (CNS) Λ4 specification (210 '乂 297mm 牦) --- · --1 ^ --- clothing ------ order ----- (read first read the back (Notes on this page, please fill in this page) 527195 Printed by the Central Bureau of Standards of the Ministry of Industry and Technology Co., Ltd. A7 1Π 5. Description of invention (k) 40% by weight or less. Furthermore, in the first aspect provided by the present invention, a preferred specific aspect of the instant solid preparation is a drug in which the total solid content is 60% by weight or less, and preferably 40% by weight or less. 100 grams of water with a solubility of less than 30 grams of saccharides and 100 grams of water with a solubility of 30 grams or more at room temperature, with a solid content weight ratio of 98: 2 ~ 80: 20, and using more than 40% by weight of all solid content, It is preferably 60% by weight or more, and is a fast-dissolving solid preparation obtained by mixing water with an incompletely dissolved amount of saccharides having a solubility of 30 g or less to 100 g of water at room temperature and removing water. The size and shape of the instant soluble solid preparation in the first aspect of the present invention are not particularly limited. For example, granules, pills, lozenges, suppositories, etc. can be prepared in the usual preparation form, and among them, it is also preferable to prepare lozenges. The manufacturing method of such an instant solid preparation can be specifically performed as follows. That is, after adding purified water to a mixed powder of a drug, a sugar having low solubility in water, and a sugar having high solubility in water, and adding it to a milky suspension, the suspension is filled into a desired preparation template. For example, in the cavity of the concave template, the solid preparation can be obtained by drying. However, a mixture of a drug and a carbohydrate having high solubility in water can also be dissolved and added in purified water. The drying to remove moisture from the suspension can be carried out by air-drying at normal temperature or by drying under reduced pressure. The instant soluble solid preparation of the present invention having the first form manufactured according to such a manufacturing method does not specifically adopt the processes of pressure molding and freeze drying, etc.-This paper size applies the Chinese National Standard (CNS) Λ4 Regulations ( 210X297 public) (Please read the notes on the back before filling this page)
527195 A7 B7 五、發明説明(?) 程,而取得於口腔内迅速崩壤、溶解之固形製劑。 另一方面,本發明所提供之第二態樣中之速溶性固形 製劑,其態樣之一為經由令藥物、糖類及聚乙烯喂咯烷 酮於有機溶劑中溶解、分散後,除去有機溶劑所取得之 速溶性固形製劑。 此類速溶性固形製劑具體而言,為經由令藥物與糖類 及聚乙烯吡咯烷麵於有機溶劑中溶解、分散,取得懸浮 液,其次將懸浮液充瑱至製劑用模板後,除去有機溶劑 而製造。 即,本發明所提供之第二形態中之速溶性固形製劑為 具有對於藥物,組合使用糖類與聚乙烯吡咯烷酮,並且 作成有機溶劑中溶解、分散之懸浮液後,除去有機溶劑 為其特徽。 此類第二形態中,速溶性固形製劑中所使用之糖類若 為溶解於水者,則無特別限制。此類糖類可使用例如單 糖類、雙糖類、寡糖類、糖醇、還原糖、異構化糖等。 更具體而言,可列舉葡萄糖、果糖、乳糖、麥芽糖、Μ 糖、木糖、海藻糖、糊精、山梨糖醇、木糖醇、甘露糖 (讀先閱讀背面之注意事項再填寫本頁)527195 A7 B7 V. Description of the invention (?) The solid preparation that quickly collapses and dissolves in the oral cavity. On the other hand, one of the aspects of the fast-dissolving solid preparation in the second aspect provided by the present invention is to remove the organic solvent by dissolving and dispersing the drug, sugar and polyethylene-fedrolidone in an organic solvent. The obtained fast-dissolving solid preparation. Specifically, such a fast-dissolving solid preparation is obtained by dissolving and dispersing a drug, a saccharide, and a polyvinylpyrrolidine surface in an organic solvent to obtain a suspension, and then filling the suspension with a template for the preparation, and then removing the organic solvent. Manufacturing. That is, the fast-dissolving solid preparation in the second aspect provided by the present invention has a special feature of using a saccharide and polyvinylpyrrolidone in combination with a drug, and dissolving and dispersing it in an organic solvent, and then removing the organic solvent. In this second aspect, the saccharide used in the instant solid preparation is not particularly limited as long as it is soluble in water. Examples of such saccharides include monosaccharides, disaccharides, oligosaccharides, sugar alcohols, reducing sugars, isomerized sugars, and the like. More specific examples include glucose, fructose, lactose, maltose, M sugar, xylose, trehalose, dextrin, sorbitol, xylitol, and mannose (read the precautions on the back before filling out this page)
、\=口 纛 經濟部中央標準局員工消費合作社印製 類上,度配 種之質硬為 些 用性之佳 此使物用較 。 同藥實分 等 共之耐成 糖 物用可形 二 藥使持固 苣與所保部 萵,據了全 、 C 中依為之 醇用劑為。劑 乳使製,化製 , 、供形量變以 9 醇上固合而般 _ 芽以性配物 一 麥種溶之加 , 、二速中添性 醇合之劑之解 糖混明製用溶 蘚或發於使之 赤獨本類同速 、單於糖共邊 醇可 述和和 本紙張尺度適用中國國家標準(〔奶)/\4規格(210'乂297公漦) 527195 A7 經濟部中央標率局員工消費合作社印製 用但劑15藥若解,供劑 為固分 製下重成烷散 使,製 ~ 令,溶又式溶 亦部成 形以40形咯分 之化以 W ,劑難。型部 雖全形 固 % 之固吡 、 _ 變般 t 中溶類醇液全 量以固 性量分部烯解 烷而一B劑機糖乙合佔 含但部 溶重成全乙溶 咯物、 製有令舉混為 物,全 速60形與聚中 。吡加性, 形之地列之佳 藥質為 ,之固,之劑 上烯添解»°固散對可水較 之性佳 中分部類%溶 mn32^tt分相例與水 含化再 態成全 ϋΜ機 。 % 聚合之 ο 溶、、體以, 所理且 形形與之重有劑 量之配速-2速解解具可中 中之, 二固,上15液製 重用同迅 1 之溶溶之亦形 劑物佳 第部物以? 合形 60使共和合 態酮好佳劑情 製藥較 之全藥%Μ 混固 為同和度配 形烷良特溶之 形和為 供將之量 U 之性0- 佳共質硬為 二咯酮其機液 固量下 提為下重 _水溶-1 再類性之佳 第吡烷,有合。明用以 所樣以60® 與速 ,糖之用較 明烯咯制類混下發服%。明態¾為’醇之 } 上及物實分 發乙吡限此用以本之量下發體量佳 W 乙得 f 以物藥耐成 本聚烯別,使 % ,用重以本具重較«1或取 —%藥據可形 於及乙特中於量面服60¾於的40,ο 醇所 明 量與依持固。,類聚無明且重方一之量,佳為上-2乙燥 説 重,雖保部 % 且糖令則發 ,30一每分重且較佳以 1 於乾 Μ40又 ,了 全量更、可,本用之另據成40而之較%之 ,, 4合 量為之重 物為者於使中 根形之 劑、量分酮後 、 五 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210X 297^"y (讀先閱讀背面之注意事項再填寫本頁), \ = 口 纛 In the case of printing by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs, the quality of hard breeding is better for some applications. The same medicine is divided into two parts, which are sugar-resistant and tangible. Two medicines are used to hold the lettuce and the protected lettuce. According to the whole, C is the alcohol agent. Emulsion milk is made, chemically prepared, and the amount of deformation is changed to 9 alcohols. _ Buds are added with the sexual formula of one wheat seed, and the two-speed medium-speed alcoholic agent is added to dissolve the sugar. Moss may be issued in the same speed, mono-sugar, and co-alcohol, which can be reconciled with the standard of Chinese paper ((milk) / \ 4 size (210 '漦 297 gong)), which is the same as the paper size. 527195 A7 Ministry of Economic Affairs Central Standards Bureau staff consumer cooperatives printed 15 but if the solution is dissolved, the supply is reconstituted into solids under the solid system, the system is made to order, and the solvent is dissolved into 40 parts. , The agent is difficult. Although the solid part of the molding part is solid, the total amount of the soluble alcohol solution in the t part is solidified and the alkylene is dissolved in a solid amount, and the organic solvent is contained in a B agent. The system has the order to be mixed, and full-speed 60 shape and gather. Pycnidol is a good medicine in the form of solids and solids, and the solution is added to the olefin »° Solid dispersion is better than water in the middle class %% mn32 ^ tt State into a full Μmachine. % Polymerization ο Dissolve, dissolve, dissolve, dispose, and reshape with a dose of the speed-speed-2 solution, which can be intermediate, two solid, the 15 liquid system reused the same as the fast dissolving solution What is the best part of the agent? Conformation 60 makes the Republican ketones better. The drug is better than the whole drug% M. It is mixed with the same degree of compatibility and the shape of the alkane is very soluble and the amount of U is 0. Its solid-liquid solid content is lowered to lower weight_water soluble -1, which is a good dipyridine, which has a good combination. It is used in the same way as 60% and speed, and the use of sugar is lower than that of ketones. Ming state ¾ is 'alcohol'. Ethyl pyridine is limited to physical distribution. This is the best amount to issue. The weight is good. B is f. The drug is cost-effective. «1 or take-% of the medicinal data can be in the form of acetic acid and 40, ο alcohol in the noodles, and the amount and dependence of the alcohol. The amount is similar to ignorance and weight, it is better to be on the top -2 dry and dry, although the insurance department% and sugar order are issued, 30 a weight per minute and preferably 1 to dry M40, the whole amount is more, more The weight of this paper is 40%, which is more than 40%. The weight of 4 is the weight of the medium-shaped agent, the amount of ketone is divided, and the five paper sizes apply the Chinese National Standard (CNS) Λ4 specification ( 210X 297 ^ " y (Read the precautions on the back before filling in this page)
經滴部中央標準局員工消費合作社印製 527195 A7 Η 7 五、發明説明(9 ) 本發明第二形態中之速溶性固形製劑之大小及形狀之 製劑形態亦無特別限定。例如,可作成通常之製劑形態 之粒劑、九劑、錠劑、栓劑等,其中亦以作成錠劑為佳。 此類速溶性固形製劑之製造方法具體而言可如下進行 。即,於藥物、糖類及聚乙烯吡咯烷酮之混合粉末中添 加有機溶劑,作成溶解、分散之懸浮液後,將此懸浮液 充填至所欲之製劑模板,例如凹型模板之穴中、乾燥則 可取得目的之固形製劑。 尚,將聚乙烯吡咯烷酮於有機溶劑中溶解並且添加至 藥物與糖類之混合粉末中亦可。又,乾燥可在常溫下通 風乾燥或以減壓乾燥進行。 依據此類製法所製造之具有第二形態之本發明的速溶 性固形製劑,並未特別採用加壓成型和冷凍乾燥等之工 程,而取得於口腔内迅速崩壞、溶解之固形製劑。 本發明所提供之第三形態中之速溶性固形製劑,其態 樣之一為經由令藥物於糖類之水溶液中溶解和/或分散 ,冷凍乾燥所取得之速溶性固形製劑。 即,本發明者檢討上述之第一及第二形態之速溶性固 形製劑,並且加上撿討根據冷凍乾燥法於口腔内等之水 分少之環境下急速溶解之固形製劑時,發現若為了於可 溶解或分散藥物之各種賦形劑之水溶液中,亦可在較短 之時間中冷凍乾燥,乃使用乳糖、海藻糖、甘露糖醇, 山梨糖醇、赤蘚糖醇、糊精等特定之耱類水溶液作為賦 形劑,並於此水溶液中,令藥物分散和/或溶解並且冷 -11- 本紙張尺度適用中國國家標準(〔奶)/\4規枱(210/ 297公錄) (請先閲讀背面之注意事項再填寫本頁)Printed by the Consumers' Cooperative of the Central Standards Bureau of Didi Department 527195 A7 Η 7 V. Description of the Invention (9) The size and shape of the instant solid preparation in the second form of the present invention are not particularly limited. For example, granules, nine preparations, lozenges, suppositories, etc. can be prepared in the usual preparation form. Among them, lozenges are also preferable. The manufacturing method of such an instant solid preparation can be specifically performed as follows. That is, add an organic solvent to the mixed powder of drugs, sugars, and polyvinylpyrrolidone to make a dissolved and dispersed suspension, and then fill this suspension into the desired preparation template, for example, in the cavity of the concave template, and obtain it by drying. Purpose solid preparation. It is also possible to dissolve polyvinylpyrrolidone in an organic solvent and add it to a mixed powder of medicine and sugar. The drying can be performed by air drying at normal temperature or by drying under reduced pressure. The instant soluble solid preparation of the present invention having the second form produced according to such a manufacturing method does not specifically adopt processes such as pressure molding and freeze-drying, but obtains a solid preparation that rapidly collapses and dissolves in the oral cavity. One of the aspects of the fast-dissolving solid preparation in the third aspect provided by the present invention is the fast-dissolving solid preparation obtained by dissolving and / or dispersing the drug in an aqueous solution of sugars and freeze-drying. That is, when the present inventors reviewed the above-mentioned first and second forms of the fast-dissolving solid preparations, and added the solid-form preparations that dissolve rapidly in an environment with little water such as in the mouth according to the freeze-drying method, they found that In aqueous solution of various excipients that can dissolve or disperse the drug, it can also be lyophilized in a short period of time. It is specifically formulated using lactose, trehalose, mannitol, sorbitol, erythritol, dextrin, etc.耱 -type aqueous solution is used as an excipient, and in this aqueous solution, the drug is dispersed and / or dissolved and cold -11- This paper size applies to Chinese national standards ([milk] / \ 4 gauge (210/297)) ( (Please read the notes on the back before filling out this page)
、1Τ 經濟部中央標準局員工消費合作社印製 527195 A7 B7 五、發明説明(、。) 凍乾燥卽可。更且,發現令分散和/或溶解藥物之糖類 水溶液濃度為在10〜30重量%之範圍,則可對於冷凍乾 燥之固形製劑賦與可耐實用程度之硬度,並且可取得於 口腔内的急速溶解性。 而且,於本發明所提供之第三形態中,速溶性固形製 劑中的較佳態樣為於乳糖、海藻糖、甘露糖醇、山梨糖 醇、赤蘚糖醇、糊精所選出之一種或二種以上糖類之10 〜30重量%水溶液中,令藥物溶解和/或分散,並且冷 凍乾燥所取得之速溶性固形製劑,特佳之態樣為溶解和 /或分散藥物之耱類水溶液為海藻糖和/或糊精水溶液 之速溶性固形製劑。 此類速溶性固形製劑具體而言,為經由令藥物於糖類 之水溶液中溶解和/或分散作成懸浮組成物,其次,將 此組成物充瑱至製劑用模板後,冷凍乾燥而製成。 即,本發明所提供之第三之速溶性固形製劑為具有令 藥物溶解和/或分散於具有待定濃度之特定的糖類水溶 液中,並且冷凍乾燥為其特擞。 此類第三形態中,速溶性固形製劑中所使用之糖類以 乳糖、海藻糖、甘露糖醇、山梨糖醇、赤蘚糖醇、糊精 為較佳,且其可單獨、或混合二種以上供使用。其中待 佳者為海藻糖和/或糊精,於本發明中若使用海藻糖和 /或糊精作為糖類,則例如於作成直徑為20niffi左右之大 錠劑形狀,亦可取得具有可耐實用硬度之固形製劑,因 此,可知其亦應付1日服用量多之藥物。尚,本發明所 -12- 本紙張尺度適用中國國家標準(CNS ) Λ4規枱(210X297公f ) (請先閲讀背面之注意事項再填寫本頁), 1T Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 527195 A7 B7 V. Description of the invention (,.) Freeze-drying is acceptable. Furthermore, it has been found that when the concentration of the aqueous solution of saccharides for dispersing and / or dissolving the drug is in the range of 10 to 30% by weight, the freeze-dried solid preparation can be given a degree of hardness that can withstand practical use, and can be rapidly obtained in the oral cavity. Solubility. Moreover, in the third aspect provided by the present invention, a preferred aspect of the instant soluble solid preparation is one selected from lactose, trehalose, mannitol, sorbitol, erythritol, and dextrin, or In a 10 to 30% by weight aqueous solution of two or more kinds of saccharides, the drug is dissolved and / or dispersed, and the fast-dissolving solid preparation obtained by freeze-drying is particularly preferable. The aqueous solution of the hydrazone type that dissolves and / or disperses the drug is trehalose. And / or a fast-dissolving solid preparation of an aqueous dextrin solution. Specifically, such a fast-dissolving solid preparation is prepared by dissolving and / or dispersing a drug in an aqueous solution of a saccharide to form a suspension composition. Next, the composition is filled with a template for a preparation and freeze-dried. That is, the third fast-dissolving solid preparation provided by the present invention has the characteristics of dissolving and / or dispersing a drug in an aqueous solution of a specific carbohydrate having a predetermined concentration, and freeze-drying it. In this third form, the saccharides used in the instant solid preparation are preferably lactose, trehalose, mannitol, sorbitol, erythritol, and dextrin, and they may be used alone or in combination. The above is for use. Among them, trehalose and / or dextrin are preferred. In the present invention, if trehalose and / or dextrin are used as sugars, for example, a large lozenge shape having a diameter of about 20 niffi can be obtained. The solid preparation of hardness, therefore, it can be seen that it can also cope with a large amount of medicine taken per day. Still, the Institute of the Invention -12- This paper size is applicable to Chinese National Standard (CNS) Λ4 gauge (210X297 male f) (Please read the precautions on the back before filling this page)
527195 A7 五、發明説明(υ ) 提供之固形製劑中所含有之藥物含量為依據每一服用之 服用量、和藥物之物性性質而異,並無特別限定。 再者,得知耱類水溶液之含量愈少,則冷凍乾燥之固 形製劑的硬度愈為降低,且糖類含量愈高則硬度愈為變 高,令冷凍乾燥耗費時間,且固形製劑之溶解時間變長 。因此,於本發明中,此些糖類較佳以10〜30重董%、 特佳以15〜25重量%溶解於水中為佳。 於本發明第三形態中之速溶性固形製劑、於藥物為不 完全溶解、或分散於耱類水溶液時,則較佳再添加後述 之分散劑。分散劑若為在調製懸浮液後,於此懸浮液被 冷凍乾燥為止可令藥物分散者,則無特別限定。 此類分散劑特佳者可列舉α -化澱粉、部分α -化澱粉 、羧甲基澱粉納、甲基纖維素、羥丙基甲基纖維素、羥 丙基纖維素、羧甲基纖維素鈉、阿拉伯橡膠粉末、黃蓍 樹膠、剌梧鋼樹膠、加堤樹膠、果膠、阿拉伯半乳聚糖 、木瓜、剌槐豆膠、瓜阿樹膠、羅望子多糖類、藻酸、 角叉菜膠、Faselerane、阽吨樹膠、Cadran、酪蛋白、 支鏈澱粉、聚乙烯吡咯烷酮、聚乙烯醇,其可為一種或 本紙張尺度適用中國國家標準(CNS ) Λ4規梠(210X 297公餘) (請先閱讀背面之注意事項再填寫本頁)527195 A7 V. Description of Invention (υ) The content of the drug contained in the solid preparations varies according to the amount of each drug taken and the physical properties of the drug, and is not particularly limited. In addition, it is learned that the less the content of the hydrazone solution, the lower the hardness of the freeze-dried solid preparation, and the higher the sugar content, the higher the hardness, which takes time for freeze-drying and the dissolution time of the solid preparation. long. Therefore, in the present invention, these sugars are preferably dissolved in water at 10 to 30% by weight, particularly preferably at 15 to 25% by weight. In the third aspect of the present invention, the fast-dissolving solid preparation is preferably added with a dispersant described later when the drug is not completely dissolved or dispersed in an amidine solution. The dispersant is not particularly limited as long as it can disperse the drug until the suspension is freeze-dried after preparing the suspension. Particularly preferred examples of such dispersants include alpha-starch, partially alpha-starch, sodium carboxymethyl starch, methyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, and carboxymethyl cellulose. Sodium, gum arabic powder, gum tragacanth, gum glutinous steel, gum gum, pectin, arabinogalactan, papaya, locust bean gum, guar gum, tamarind polysaccharides, alginic acid, carrageen Gum, Faslerane, xanthan gum, Cadran, casein, amylopectin, polyvinylpyrrolidone, polyvinyl alcohol, which can be one or this paper size applies Chinese National Standard (CNS) Λ4 Regulations (210X 297 public) ( (Please read the notes on the back before filling out this page)
,之 及製 下劑 小之 以製 大常 ¾明 之通 量發 α 劑成 重本燥製作 CO 礙乾形可 之妨凍固 , 液會冷性如 浮不行溶例 懸其進速 。 為因中之定 常 ,間中限 通下時態別3-。 量以短形特-1 用加%在三無 使添量可第亦 供之重且類態 上劑 1 ,此形 以散為性之劑 種分望解明製 二類期溶發之 合此別速本狀 混特急 形 經濟部中央標準局員工消費合作社印製 經濟部中央標準局員工消費合作社印製 527195 Α7 Β7 五、發明説明(π ) 雨形態之粒劑、丸劑、錠劑、栓劑等,其中亦以作成錠 劑為佳。 此類速溶性固形製劑之製造方法具體而言可如下進行 。即,將視需要之分散劑、及後述之香料、甘味料等之 其他添加物,與藥物共同於糖類之水溶液中溶解和/或 分散作成懸浮組成物,其次,將此組成物充填至所欲之 製劑模板,例如凹型模板之穴中,冷凍乾燥則可取得目 的的固形製劑。 依據此類製造方法所製造之本發明第三形態中之速溶 性固形製劑,具有可耐實用之硬度,加上具有即使未與 水共同服用,於口腔内等中之崩壞、溶解性為非常迅速 之特徽。 以上本發明所提供之第一至第三形態中的速溶性固形 製劑所使用之藥物種類,並無特別限定,且可配合各種 藥物。 此類藥物之代表性物質,可例示例如以下之藥物。 催眼鎮靜劑、抗癲癇藥、解熱鎮痛消炎藥、興奮藥、 覺醒藥、鎮翬藥、精神神經同藥等之中樞神經用藥;骨 骼肌鬆弛藥.自律神經藥、自律神經組斷藥、植物製劑 等之末梢神經用藥;眼科用藥、耳鼻科用藥等之感覺器 官用藥;強心藥、不整脈用藥、利尿藥、降血壓藥、血 管增強藥、血管收縮藥、血管擴張藥、動脈硬化用藥等 之循環器用藥。 再者可列舉呼吸促進藥、鎮咳去痰藥等之呼吸器官用 本紙張尺度適用中國國家標準(CNS ) Α4規枱(210Χ297公# ) (讀先閱讀背面之注意事項再填寫本頁 、-u t 527195 經漓部中央標準局員工消費合作社印製 A7 五、發明説明(d ) 藥;消化性潰瘍用藥、健胃消化藥、制酸藥、下劑、利 膽藥、整腸藥等之消化器官用藥;荷爾蒙藥、抗荷爾蒙 等之荷爾蒙藥;尿遒消毒藥、子宮收縮藥、泌尿生殖器 官用藥。痔瘡用藥、肛門用藥等之泌尿生殖器官及肛門 用藥;維生素、滋養強狀改質劑、血液及體液用藥、肝 臓疾病用藥、解毒藥、習慣性中毒用藥、通風治療劑、 酵素製劑、耱尿病治療藥等之代謝性醫藥品;細胞賦活 用藥、腫瘤用藥等之組織細胞之機能用翳藥品;抗生素 、化學療法藥、抗原蟲藥、驅蟲藥等之對抗病原生物之 翳藥品;生物鹸条麻藥、非生物鹸条麻藥等之麻藥等。 此些藥物可以一種或混合二種以上供使用。 此些藥物可為固體、粉體、或液體形狀。固體藥物若 進行撤細粉碎等、作成撤粉末供使用,則在口腔内崩壤 、溶解時觸感滑順、服用感良好。又,本發明所用之藥 物亦可為微膠囊、徹球、毫撤膠囊、毫徹球般之被膠囊 化者。又,亦可將二種以上之藥物另層配置。 本發明所提供之上述第一形態至第三形態中之速溶性 固形製劑,於任何情況中,亦可在不令其崩壞、溶解性 和硬度顯箸惡化之範圍内,添加其他配合成分、及作為 分散劑之天然或合成之高分子化合物。又,視所欲,可 再配合任何一種以上之甘味料、酸味料、香料、著色劑。 此類天然或合成高分子化合物之具體例可列舉馬鈐薯 澱粉、玉米澱粉、米澱粉、小麥澱粉、α-化澱粉、部分 ot-化澱粉、羧甲基澱粉鈉、羥丙基澱粉等之澱粉及其衍 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公# ) (請先閲讀背面之注意事項再填寫本頁)In addition, the preparation agent is small, and the preparation is usually made with a flux of α. The amount of α agent is used to make the weight dry. The CO can be dried and frozen, and the liquid may be frozen. If the liquid is not soluble, the speed may be suspended. Because of the regularity in the middle, the intermediate tense state is 3-. The amount is in the form of short form -1. Adding% in San Wu makes the amount of addition can also provide the weight and kind of agent 1. This form is based on the loose nature of the drug. Printed by the Central Standards Bureau of the Ministry of Economic Affairs and printed by the Consumer Cooperatives of the Ministry of Economic Affairs. Printed by the Central Consumers Bureau of the Ministry of Economics and printed by the Consumer Cooperatives of the Central Standards Bureau. 527195 Α7 Β7 V. Description of the invention (π) Granules, pills, lozenges, suppositories, etc. in the form of rain Among them, it is better to make lozenges. The manufacturing method of such an instant solid preparation can be specifically performed as follows. That is, a dispersant as needed, and other additives such as flavors and sweeteners described later are dissolved and / or dispersed in an aqueous solution of sugars together with the drug to form a suspension composition. Next, this composition is filled to the desired The preparation template, such as the cavity of the concave template, can be freeze-dried to obtain the intended solid preparation. The fast-dissolving solid preparation of the third aspect of the present invention manufactured by such a manufacturing method has a practical hardness, and has a disintegration and solubility in the oral cavity and the like even if it is not taken with water. Quick emblem. There are no particular limitations on the types of drugs used in the instant soluble solid preparations of the first to third aspects provided by the present invention, and various drugs can be blended. Representative examples of such drugs include the following drugs. Eye sedatives, antiepileptics, antipyretics, analgesics, anti-inflammatory drugs, stimulants, awakening drugs, sedatives, neuropsychiatric drugs and other central nervous system drugs; skeletal muscle relaxation drugs. Autonomic nerve drugs, autonomic nerve group medication, plant preparations Peripheral nerve medications; ophthalmic medications, otolaryngology medications, and other sensory organ medications; cardiotonic medications, irregular pulse medications, diuretics, antihypertensive medications, vasoconstrictors, vasoconstrictors, vasodilators, and arteriosclerosis medications. Furthermore, it can be used for respiratory organs such as breath-promoting drugs, antitussive and expectorants, etc. This paper is applicable to Chinese National Standards (CNS) A4 Regulations (210 × 297 公 #) (Read the precautions on the back before filling in this page, -ut 527195 A7 printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Lithology 5. Description of the Invention (d) Medicines; Peptic ulcer medicines, stomach digestion medicines, antacids, lowering agents, choleretics, intestinal medicines and other digestive organ medicines ; Hormones, anti-hormones and other hormones; urinary urinary disinfectants, uterine contractions, urogenital drugs. Hemorrhoids, anal drugs, and other urogenital and anal drugs; vitamins, nourishing strong modifiers, blood and Metabolic medicines such as body fluid medicine, liver disease medicine, detoxification medicine, habitual poison medicine, ventilation therapy agent, enzyme preparation, urination medicine medicine, etc .; cell activation medicine, tumor medicine, etc. Antibiotics, chemotherapeutic drugs, antiprotozoal drugs, insect repellent drugs, etc. Anti-pathogenic drugs; biological tampon drugs, non-biological tampons Anesthetics, etc. These drugs can be used alone or in combination of two or more. These drugs can be solid, powder, or liquid. If solid drugs are finely pulverized, etc., and used as powders, they can be used in the oral cavity. It disintegrates internally, feels smooth when dissolved, and has a good feeling of taking. In addition, the medicine used in the present invention can also be microcapsules, cutballs, millicapsules, and milliballs. Two or more drugs are arranged in another layer. The fast-dissolving solid preparations in the first to third forms provided by the present invention can, in any case, not cause its disintegration, solubility and hardness to deteriorate significantly. Within the scope, other compounding ingredients, and natural or synthetic high molecular compounds as dispersants are added. Also, if desired, any one or more sweeteners, sour agents, spices, and colorants can be further compounded. Such natural or Specific examples of synthetic polymer compounds include starches such as potato starch, corn starch, rice starch, wheat starch, α-chemical starch, partially ot-chemical starch, sodium carboxymethyl starch, and hydroxypropyl starch. Their derivatives This paper scales applicable Chinese National Standard (CNS) A4 size (210X297 male #) (Please read the notes and then fill in the back of this page)
經滴部中央標準局員工消費合作社印製 527195 A7 B7 五、發明説明(4 ) 生物;結晶纖維素、甲基纖維素、低取代度羥丙基纖維 素、乙基纖維素、羧甲基纖維素、羧甲基纖維素鈣、羧 甲基纖維素鈉、低取代度羧甲基纖維素鈉、交聯羧甲基 纖維素鈉、醋酸纖維素、醋酸酞酸纖維素、羥内基甲基 纖維素酞酸酯、羥丙基甲基纖維素醋酸酯琥珀酸酯、羧 甲基乙基纖維素、結晶纖維素、羧甲基纖維素鈉等之纖 維素及其衍生物等。 再者,可列舉阿拉伯橡膠粉末、黃蓍樹膠、剌梧桐樹 膠、加堤樹膠、果膠、阿拉伯半乳聚糖、木瓜、剌槐豆 膠、瓜阿樹膠、羅望子多糖類、藻酸、角叉菜膠、 Faselerane、阽吨樹膠、Cadran、酪蛋白、支鏈澱粉、 白蛋白等之天然高分子化合物;聚乙烯吡咯烷酮、聚醋 酸乙烯酯、聚乙二醇、聚乙烯醇、胺烷基甲基丙烯酸酯 共聚物E、胺烷基甲基丙烯酸酯共聚物RS、甲基丙烯酸 共聚物S、羧乙烯基聚合物、聚乙烯基乙縮醛二乙胺基 醋酸酯、二甲基聚矽氣烷等之合成高分子化合物。 又,甘味料之具體例可列舉甘草甜、甘草酸二鈉、甘 草酸三鈉、蛇菊、蛇菊苜、L e v 〇 d i a s i d e、糖精、糖精 鈉、阿斯巴甜等。 再者,酸味料之具體例可列舉檸檬酸、酒石酸、蘋果 酸等,香料之具體例可列舉草莓、檸檬、檸檬酸橙、橙 、薄荷、薄荷油Λ薄荷醇等,著色料之具體例可列舉焦 糖、Anato萃取色素、/3-胡蘿萄素、Beet Red等。 -16- 本紙張尺度適用中國國家標準(CNS ) Λ4規掊(210X 297公f ) (請先閱讀背面之注意事項再填寫本頁)Printed by the Consumers' Cooperative of the Central Standards Bureau of Didi Ministry 527195 A7 B7 V. Description of the invention (4) Biological; crystalline cellulose, methyl cellulose, low-substituted hydroxypropyl cellulose, ethyl cellulose, carboxymethyl fiber Cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, sodium carboxymethyl cellulose with low degree of substitution, croscarmellose sodium, cellulose acetate, cellulose acetate phthalate, hydroxymethyl methyl Cellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, crystalline cellulose, cellulose such as sodium carboxymethylcellulose, and derivatives thereof. In addition, gum arabic powder, gum tragacanth, gum sycamore, gum, gum, pectin, arabinogalactan, papaya, locust bean gum, guar gum, tamarind polysaccharides, alginic acid, carrageenan Natural polymer compounds such as carrageenan, Faselerane, xanthan gum, Cadran, casein, amylopectin, albumin, etc .; polyvinylpyrrolidone, polyvinyl acetate, polyethylene glycol, polyvinyl alcohol, amino alkyl methyl Acrylic acrylate copolymer E, amine alkyl methacrylate copolymer RS, methacrylic acid copolymer S, carboxyvinyl polymer, polyvinyl acetal diethylamino acetate, dimethylpolysiloxane Synthetic polymer compounds such as alkanes. Specific examples of the sweetener include glycyrrhizin, disodium glycyrrhizinate, trisodium glycyrrhizinate, snake daisy, stevia alfalfa, Levo d i a s i de, saccharin, sodium saccharin, and aspartame. In addition, specific examples of the sour material include citric acid, tartaric acid, and malic acid, and specific examples of the flavor include strawberry, lemon, citrate, orange, mint, and peppermint oil menthol. Specific examples of the coloring material include Examples include caramel, Anato extract, / 3-carotene, and Beet Red. -16- This paper size applies Chinese National Standard (CNS) Λ4 Regulation (210X 297 male f) (Please read the precautions on the back before filling this page)
、1T .0 經滴部中央標準局員工消費合作社印製 527195 A 7 B7 五、發明説明(< ) 實施例 以下列舉實施例,更詳細說明本發明所提供之第一形 態至第三形態之速溶性固形製劑,但本發明並不被此些 實施例所規定。 A:笛一形態之谏溶#因形餺麵 啻旃例1 將四氟硫安定(Quazepam)37.5克、甘露糖醇415克、 阿斯匹甜5克及卜薄荷醇2.5克均勻混合。其次,於此 混合粉末中添加混合蔗糖40克溶解於精製水200克之液 體,取得乳狀之懸浮液。將此懸浮液以各280毫克充填 至直徑9ηιιι之凹型穴中,並於301C通風乾燥24小時,取 得本發明之速溶性製劑。 實1盥—2_ 將四氟硫安定37.5克、甘露糖醇415克、阿斯匹甜5 克及1_薄荷醇2.5克及蔗糖40克均勻混合。其次,於此 混合粉末中添加混合精製水200克之液髏,取得乳狀之 懸浮液。將此懸浮液以各280毫克充填至直徑9am之凹型 穴中,並於3010通風乾燥24小時,取得本發明之速溶性 製劑。 m.MJSL2u 將鹽酸每可靜(Meclizine Hydrochloride),順丁嫌 二酸氛苯胺2克、鹽酸吡哆醇20克、甘露糖醇452克、 乳糖400克、阿斯巴甜24克及1-薄荷醇12克均勻混合, 並且於蔗糖80克溶解於精製水420克之液中投入混合, 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公餘) (請先閱讀背面之注意事項再填寫本頁)1T.0 Printed by the Consumer Standards Cooperative of the Central Standards Bureau of Didi Ministry 527195 A 7 B7 V. Description of the Invention () Examples The following examples are given to explain in more detail the first to third forms provided by the present invention. A fast-dissolving solid preparation, but the present invention is not limited by these examples. A: 笛 一 FORM 的 谏 解 # 因 形 馎 面 啻 旃 Example 1 37.5 g of tetrafluorosulfan (Quazepam), 415 g of mannitol, 5 g of aspirin and 2.5 g of menthol are evenly mixed. Next, a solution of 40 g of sucrose mixed with 200 g of purified water was added to the mixed powder to obtain a milky suspension. This suspension was filled with 280 mg each into a concave cavity having a diameter of 9 μm, and dried at 301 C for 24 hours to obtain the instant soluble preparation of the present invention. To make a toilet—2_, mix 37.5 grams of tetraflurane diazepam, 415 grams of mannitol, 5 grams of aspirin, 2.5 grams of 1-menthol and 40 grams of sucrose. Next, a liquid suspension of 200 g of purified water was added to the mixed powder to obtain a milky suspension. This suspension was filled into concave cavities with a diameter of 9am with 280 mg each, and air-dried at 3010 for 24 hours to obtain the instant soluble preparation of the present invention. m.MJSL2u Meclizine Hydrochloride, 2 grams of maleic acid aniline, 20 grams of pyridoxine hydrochloride, 452 grams of mannitol, 400 grams of lactose, 24 grams of aspartame and 1-menthol 12 grams of alcohol are evenly mixed, and mixed in 80 grams of sucrose dissolved in 420 grams of purified water. This paper size applies the Chinese National Standard (CNS) A4 specification (210X297). (Please read the precautions on the back before filling in this. page)
527195 經漓部中央標準局負工消費合作社印製 A7 五、發明説明(4 ) 取得乳狀之懸浮液。將此懸浮液以各365毫克充填直徑 llrain之凹型穴中,並於3〇υ通風乾燥36小時,取得本發 明之速溶性製劑。 奮施例4 將濕羊藿萃取物1克、山株萃取物2克、松香7.5克 、何首烏乾燥萃取物1.5克、人參乾燥萃取物4.5克、地 黃乾燥萃取物1克、麥門冬乾燥萃取物、雙苯硫胺0.5克 。硫酸吡多醇0.5克、維生素123毫克、咖啡因2.5克、 結晶纖維素10克、甘露糖醇120克、海藻糖2克及蔗糖 1 . 1克。於此混合粉末中添加精製水60克,取得乳狀之 懸浮液。將此懸浮液以各219.6毫克充填至直徑2〇1〇18之 凹型穴中,並於301C下通風乾燥12小時後,減壓乾燥1 小時,取得本發明之速溶性製劑。 ILIMJl 將鹽酸他瘍平(Pirenzepine Hydrochloride)25克、 甘露糖醇160克、乳糖、蔗糖20克、玉米澱粉20克、阿 斯巴甜2克及1-薄荷醇1克均勻混合,並於其中投入混 合以精製水100克,取得乳狀之懸浮液。將此懸浮液以 各348毫克充填至直徑llmin之凹型穴中,並於301下通 風乾燥1 2小時後,減壓乾燥1 2小時,取得本發明之速溶 性製劑。 試駱例1 將上述實施例1至實施例5所製造之各製劑,以富山 産業製錠劑硬度計(TH-303RP型)測定其硬度。又,使用 - 1 8 _ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公録) (請先閱讀背面之注意事項再填寫本頁)527195 Printed by the Central Bureau of Standards, Ministry of Work, Consumer Cooperatives A7 V. Description of Invention (4) Obtain a milky suspension. This suspension was filled with 365 milligrams of concave cavities with a diameter of llrain, and dried in aeration for 30 hours at 30 ° to obtain the instant soluble preparation of the present invention. Fenshi Example 4 1 g of wet sheep's root extract, 2 g of mountain plant extract, 7.5 g of rosin, 1.5 g of dried extract of Polygonum multiflorum, 4.5 g of dried extract of ginseng, 1 g of dried extract of Rehmannia glutinosa, and dried asparagus Extract, 0.5 g of diphenylthiamine. 0.5 g of pyridosyl sulfate, 123 mg of vitamins, 2.5 g of caffeine, 10 g of crystalline cellulose, 120 g of mannitol, 2 g of trehalose and 1.1 g of sucrose. 60 g of purified water was added to this mixed powder to obtain a milky suspension. This suspension was filled into concave cavities with a diameter of 201,018 with 219.6 mg each, and then air-dried at 301 C for 12 hours, and then dried under reduced pressure for 1 hour to obtain the instant soluble preparation of the present invention. ILIMJl 25g of Pirenzepine Hydrochloride, 160g of mannitol, 20g of lactose, 20g of sucrose, 20g of corn starch, 2g of aspartame, and 1g of 1-menthol are mixed and put into it Mix with 100 g of purified water to obtain a milky suspension. This suspension was filled into concave cavities with a diameter of llmin at 348 mg each, and then air-dried at 301 for 12 hours, and then dried under reduced pressure for 12 hours to obtain the instant soluble preparation of the present invention. Test Example 1 The hardness of each of the preparations manufactured in the above Examples 1 to 5 was measured with a Toyama Industrial Tablet Hardness Tester (TH-303RP type). Also, use-1 8 _ This paper size applies to China National Standard (CNS) A4 specification (210X297). (Please read the precautions on the back before filling this page)
527195 A7 Η 7 五、發明説明(π ) 精製水作為試驗液,並且依據日本藥典第13販崩鳆試驗 法测定其崩壤時間。並且,測定口腔内溶解時間。 其結果整理於表1。 表1 :硬度、崩壞時間及口腔内溶解時間 實施例 硬度(Kg) (10値之平均值) 崩壤時間(秒) (6個之平均值) 口腔内溶解時間(秒) (3人之平均值) 實施例1 6.62 66.0 53,3 實施例2 4.83 51.8 46.7 實施例3 3.54 37.3 38.0 實施例4 6.37 79· 8 58.3 實施例5 8.73 23· 2 47.3 (請先閲讀背面之注意事項再填寫本頁) 、1Τ . 經漓部中央標準局貝工消費合作社印製 如表中之結果所蘭明般,本發明之固形製劑為硬度亦 可耐實用,且口腔内之溶解時間亦大約為1分鐘以内, 可理解其為特別優異之製劑。 奮施例6 將雙氣酚酸鈉(Diclophenac Sodium)25克、甘露糖醇 170克、檸檬酸12克、玉米澱粉20克、阿斯巴甜2克及 香料1克均勻混合,並且於蔗糖20克溶解於精製水克 本紙張尺度適用中國國家標準(CNS ) Λ4規掐(210Χ?97公# ) 經漓部中央標準局貝工消費合作社印製 527195 A7 B7 五、發明説明(J) 之溶液中投入混合,取得乳狀之懸浮液。將此懸浮液以 各350毫克充填至直徑lOBiffl之凹型穴中,並於30¾下通 風乾燥8小時後,減壓乾燥1 0小時,取得本發明之速溶 性製劑。 將炎痛喜康(Piroxicam)20克、甘露糖醇175克、檸檬 酸12克、玉米澱粉20克、阿斯巴甜2克及香料1克均勻 混合,並且於蔴耱20克溶解於精製水100克之溶液中投 入混合,取得乳狀之懸浮液。將此懸浮液以各350毫克 充填至直徑lOrnm之凹型穴中,並於30 1C下通風乾燥8小 時後,減壓乾燥10小時,取得本發明之速溶性製劑。 奮渝例8 將雙苯硫胺25克、甘露糖醇196克、阿斯巴甜2克及 香料2克均勻混合,並且於蔗耱20克溶解於精製水120 克之溶液中投入混合,取得乳狀之懸浮液。將此懸浮液 以各365毫克充填至直徑lOinm之凹型穴中,並於30¾下通 風乾燥8小時後,減壓乾燥1 0小時,取得本發明之速溶 性製劑。 測定實施例6至實施例8所製造之各製劑的口腔内溶 解時間。其結果示於表2。 -20- 本紙張尺度適用中國國家標準(〇奶)/\4規梠(210乂297公§) (請先閲讀背面之注意事項再填寫本頁)527195 A7 Η 7 V. Description of the invention (π) Refined water is used as the test solution, and its collapse time is measured according to the Japanese Pharmacopoeia 13th Disintegration Test. Then, the dissolution time in the oral cavity was measured. The results are summarized in Table 1. Table 1: Hardness, disintegration time and dissolution time in the mouth Example hardness (Kg) (average of 10 値) Disintegration time (seconds) (average of 6) Dissolution time in the mouth (seconds) (of 3 persons) Average value) Example 1 6.62 66.0 53,3 Example 2 4.83 51.8 46.7 Example 3 3.54 37.3 38.0 Example 4 6.37 79 · 8 58.3 Example 5 8.73 23 · 2 47.3 (Please read the precautions on the back before filling in this (Page), 1T. Printed by the Central Bureau of Standards, Shellfish Consumer Cooperative, as the results in the table show, the solid preparation of the present invention has hardness and can withstand practical use, and the dissolution time in the mouth is about 1 minute. Within this range, it is understood that it is a particularly excellent preparation. Fenshi Example 6 25 grams of Diclophenac Sodium, 170 grams of mannitol, 12 grams of citric acid, 20 grams of corn starch, 2 grams of aspartame and 1 gram of spices, and mixed with sucrose 20 Gram dissolved in refined water Gram paper size Applicable to Chinese National Standards (CNS) Λ4 Regulations (210 ×? 97 公 #) Printed by the Shell Standard Consumer Cooperative of the Central Standards Bureau of the Ministry of Lithuania 527195 A7 B7 V. Solution for Invention (J) Mix in medium to obtain a milky suspension. This suspension was filled with 350 mg each into concave cavities with a diameter of 1 OBiffl and dried in the air at 30 ° C for 8 hours, and then dried under reduced pressure for 10 hours to obtain the instant soluble preparation of the present invention. Mix 20 grams of Piroxicam, 175 grams of mannitol, 12 grams of citric acid, 20 grams of corn starch, 2 grams of aspartame and 1 grams of spices, and dissolve in 20 grams of mochi in purified water 100 g of the solution was put into a mixture to obtain a milky suspension. This suspension was filled with 350 mg each into concave cavities with a diameter of 10 nm, and dried under ventilation at 30 ° C for 8 hours, and then dried under reduced pressure for 10 hours to obtain the instant soluble preparation of the present invention. Fenyu Example 8 25 grams of diphenylthiamine, 196 grams of mannitol, 2 grams of aspartame, and 2 grams of spices were mixed uniformly, and 20 grams of sucrose was dissolved in 120 grams of purified water and mixed to obtain milk. Like a suspension. This suspension was filled into concave cavities with a diameter of 10 inm at 365 mg each, and then dried in the air at 30 ° C for 8 hours and then dried under reduced pressure for 10 hours to obtain the instant soluble preparation of the present invention. The oral dissolution time of each of the preparations produced in Examples 6 to 8 was measured. The results are shown in Table 2. -20- This paper size applies Chinese National Standard (〇 奶) / \ 4 \ (210 乂 297 公 §) (Please read the notes on the back before filling this page)
527195 Α7 Β7 五、發明説明(π ) 表2 : 口腔内溶解時間 實施例 口腔内溶解時間(秒) (3人之平均值) 實施例6 26 . 3 實施例7 26 . 7 實施例8 18.7 哪衣-- (請先閱讀背面之注意事項再填寫本頁) 、11 如表中之結果所蘭明般,本發明之製劑於口腔内之溶解 時間亦大約為30秒以内,可理解其為特別優異之製劑。 Β :镜二形耱夕谏溶袢因形製割 奮施例9 .纛. 將四氟硫安定15克、蔗糖169, 5克、玉米澱粉50克、 經濟部中央標準局員工消費合作社印製 阿斯匹甜2克及卜薄Μ醇0,5克均勻混合。其次,於此 混合粉末中,添加聚乙烯吡咯烷園12.5克溶解於乙醇 15 0克中之溶液並混合則取得懸浮液。將此懸浮液以各 400毫克充填至直徑9πιιη之凹型穴中,並於30C通風乾燥 後,減壓乾燥1 2小時,取得本發明之速溶性製劑。 奮_例〗0〜啻偷例1 9 實施例10〜19為使用以下記載之糖,取代實施例9所 使用之蔗糖,其他為同樣處理,取得本發明之速溶性製 -21- 本紙張尺度適用中國國家標準(CNS ) Λ4规掊(210 Χ 297公龄) 527195 A7 五、發明説明(% ) 爾。 實施例1 0 ...海藻糖 實施例11...甘露耱醇 實施例1 2 ...赤蘚糖醇 實施例1 3 ...山梨糖醇 實施例1 4 ...乳糖 實施例15...粉末還原麥芽耱耱漿 實施例1 6 ...木耱醇 實施例1 7 ...葡萄耱 實施例1 8 ...果糖 實施例19.,.糊精 依據試驗例1同樣之方法,測定實施例9至實施例1 9 所製造之各製劑之硬度。又,测定崩壞時間及口腔内溶 解時間。 其結果整理於表3中。 (請先閲讀背面之注意事項再填寫本頁527195 Α7 Β7 V. Description of the invention (π) Table 2: Intraoral dissolution time Example Intraoral dissolution time (seconds) (average of 3 persons) Example 6 26.3 Example 7 26. 7 Example 8 18.7 Which Clothing-(Please read the precautions on the back before filling this page), 11 As the results in the table show, the dissolution time of the preparation of the present invention in the oral cavity is also within 30 seconds, which can be understood as a special Excellent formulation. Β: Mirror-shaped shape Xixi 耱 Solution 袢 due to shape cutting Example 9: 施. 15 grams of tetrafluorosulfan stabilization, 169,5 grams of sucrose, 50 grams of corn starch, printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs Mix 2 grams of aspirin and 0,5 grams of bubolol. Next, to this mixed powder, a solution of 12.5 g of polyvinylpyrrolidine garden dissolved in 150 g of ethanol was added and mixed to obtain a suspension. This suspension was filled with 400 mg each into concave cavities with a diameter of 9 μm, and dried under ventilation at 30 C, and then dried under reduced pressure for 12 hours to obtain the instant soluble preparation of the present invention. Fen_Example〗 0 ~ 啻 Steal example 1 9 Examples 10 to 19 use the sugars described below instead of the sucrose used in Example 9, and the others are treated in the same way to obtain the instant soluble system of the present invention. Applicable to China National Standard (CNS) Λ4 Regulations (210 x 297 males) 527195 A7 V. Description of Invention (%). Example 1 0 ... Trehalose Example 11 ... Mannitol Example 1 2 ... Erythritol Example 1 3 ... Sorbitol Example 1 4 ... Lactose Example 15 ... Powder reduced malt mash pulp Example 16 ... Mutyl alcohol Example 17 ... Grape mash Example 18 ... Fructose Example 19. Dextrin is the same as Test Example 1 By the method, the hardness of each preparation manufactured in Examples 9 to 19 was measured. The disintegration time and the oral dissolution time were measured. The results are summarized in Table 3. (Please read the notes on the back before filling this page
、1T 纛 經漓部中央標準局貝工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) Α4規枱(210Χ 297公# ) 527195 A7 五、發明説明(Μ ) 經濟部中央標準局員工消費合作社印製 表3:硬度、崩壤時間及口腔内溶解時間 硬度(Kg) 崩壞時間(秒) 口腔内溶解時間(秒) 實施例 (10値之平均值) (6値之平均值) (3人之平均值) 實施例9 1.56 8.0 37.7 實施例10 1.80 6·3 37*3 實施例11 2.12 6.3 18.3 實施例12 2.53 6,5 15.3 實施例13 2.01 9·5 31.0 實施例14 L95 7·2 16,3 實施例15 4.43 12.5 26.3 實施例16 2.88 6.5 13.3 實施例17 1·92 10·3 17.0 實施例18 3.59 16.3 31.0 實施例19 2.22 15·3 41.3 -23- (請先閱讀背面之注意事項再填寫本頁) 、1Τ 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210Χ 297公錄) 527195 A7五、發明説明(》) 如表中之結果所瞄明般,本發明之製劑為硬度亦可耐 實用,且口腔内之溶解時間亦大約為30秒以内,可理解 其為特別優異之製劑。 實—愈 將四氟硫安定15克、蔗糖177克、玉米澱粉50克、阿 斯匹甜2克、卜薄荷醇0.5克及聚乙烯吡咯烷酬5克均 勻混合。其次,於此混合粉末中添加150克並混合,取 得懸浮液。將此懸浮液以各400毫克充填至直徑9ιιιιη之凹 型穴中,並於30 υ通風乾燥3小時後,減壓乾燥12小時 ,取得本發明之速溶性製劑。 窨施例2 1 除了將實施例20之簾糖量變更成157克、聚乙烯吡咯 烷酮量變更成25克以外,同樣處理,取得本發明之速溶 性製劑。 奮施例22 除了將實施例20之蔗糖量變更成144.5克、聚乙烯吡 咯烷酬量變更成37.5克以外,同樣處理,取得本發明之 速溶性製劑。 經滴部中央標準局員工消費合作社印製 成理 更處 變樣 量同 耱 , 蔗外 之以 20克 例55 施成 實更 將變 了量 除 _ 〇 烷劑 成 更 變 量 糖 蔗 之 ο 2 例 施 實 將 了 除 本纸張尺度適用中國國家標準(CNS ) Λ4規掊(210Χ297公# ) 咯 比 ffr 烯 乙 聚 克 0 之 1X 例 較 比 得 取 烯 乙 聚 去 除 Λ 克 (請先閲讀背面之注意事項再填寫本頁)、 1T Printed by the Central Bureau of Standards, Ministry of Standards and Industry, Cooperating Cooperatives. This paper is printed in accordance with Chinese National Standards (CNS) A4 (210 × 297) # 527195 A7 V. Description of Invention (M) Staff Consumption of Central Standards Bureau, Ministry of Economic Affairs Printed by Cooperatives Table 3: Hardness, soil collapse time, and oral dissolution time Hardness (Kg) Disintegration time (seconds) Oral dissolution time (seconds) Example (average of 10 値) (average of 6 値) ( Average of 3 people) Example 9 1.56 8.0 37.7 Example 10 1.80 6 · 3 37 * 3 Example 11 2.12 6.3 18.3 Example 12 2.53 6,5 15.3 Example 13 2.01 9 · 5 31.0 Example 14 L95 7 · 2 16,3 Example 15 4.43 12.5 26.3 Example 16 2.88 6.5 13.3 Example 17 1.92 10 · 3 17.0 Example 18 3.59 16.3 31.0 Example 19 2.22 15 · 3 41.3 -23- (Please read the note on the back first Please fill in this page for further information), 1T This paper size applies the Chinese National Standard (CNS) Λ4 specification (210 × 297 public records) 527195 A7 V. Description of the invention (") As indicated by the results in the table, the preparation of the present invention is Hardness is also resistant to practical use and dissolves in the mouth Also between about 30 seconds, it is understood that the formulation is particularly excellent. Shi-yu Mix 15 grams of tetrafluorosulfanil, 177 grams of sucrose, 50 grams of corn starch, 2 grams of aspirin, 0.5 grams of menthol and 5 grams of polyvinylpyrrolidine. Next, 150 g of this mixed powder was added and mixed to obtain a suspension. This suspension was filled with 400 mg each into concave cavities with a diameter of 9 μm, and dried under ventilation for 3 hours at 30 υ, and then dried under reduced pressure for 12 hours to obtain the instant soluble preparation of the present invention. Example 2 1 Except that the amount of the curtain sugar of Example 20 was changed to 157 g, and the amount of polyvinylpyrrolidone was changed to 25 g, the same treatment was performed to obtain the instant soluble preparation of the present invention. Example 22 Except that the amount of sucrose in Example 20 was changed to 144.5 g and the amount of polyvinylpyrrolidine was changed to 37.5 g, the instant treatment was obtained in the same manner as in the present invention. After printing by the Central Standards Bureau employee consumer cooperative, the processing volume is the same. The amount of sugar cane is changed to 20 grams. Example 55 is used to change the amount of the _ alkane agent into a more variable sugar cane. 2 Examples In addition to the paper size applicable to Chinese National Standards (CNS) Λ4 Regulations (210 × 297 公 #) Slight ratio ffr 1X of ethylene polymer g 0 For comparison, take ethylene polymer to remove Λ g (please read the note on the back first) (Fill in this page again)
527195 A7 B7 五、發明説明(W ) 吡咯烷酮以外,其他為同樣處理,取得比較例2之製劑。 試驗例4 同試驗例1處理、測定上述實施例20至實施例22所製 造之本發明製劑、及比較例1及2製劑之硬度、硼壤時 間。 其結果整理於表4 。 (讀先閱讀背面之注意事項再填寫本頁 經漓部中央標準局員工消費合作社印製 表3:硬度、崩壞時間及口腔内溶解時間 聚乙烯吡咯烷酮之 硬度(Kg) 崩壤時間(秒) 實施例 之添加量(%) (10個之平均值) (6個之平均值) 實施例20 2 1,03 6.0 實施例21 10 2.80 55.0 實施例22 15 5.83 58.0 比較例1 22 8.24 271.8 比較例2 0 0,30 1.2 如表中之結果所蘭明般,未添加聚乙烯吡咯烷國之比 較例2製劑為非常脆。又,聚乙烯吡咯烷酬添加量多之 比較例1製劑,其崩壤時間變長至4分鐘以上。相對地 本紙張尺度適用中國國家標準(CNS ) Λ4規梠(210X297公犛) 、-5口 .猶. 527195 經漓部中央標準局貝工消費合作社印製 A7 Η 7 五、發明説明() ,本發明之製劑為硬度亦可耐實用,且崩壞時間亦為迅 速,可理解為特別優異之製劑。 za. 將四氟硫安定15克、蔗糖179,5克、玉米澱粉50克、 阿斯匹甜2克、1-薄荷醇0.5克及聚乙烯吡咯烷酮2.5克 均勻混合。其次,於此混合粉末中添加105克及水45克 之混合液並混合,取得懸浮液。將此懸浮液以各400毫 克充瑱至直徑9βιιπ之凹型穴中,並於30t!通風乾燥3小 時後,減壓乾燥12小時,取得本發明之速溶性製劑。 此製劑之硬度為1.85公斤(10個之平均值),崩壞時間 為8.3秒(6個之平均值),口腔内之溶解時間為37,3秒 (3人之平均值)。 奮施例2 4 將鹽酸吡哆醇30克、赤蘚糖醇151克、玉米澱粉50克 、檸檬酸1克、阿斯巴甜1克及香料2克均勻混合。其 次於此混合粉末中,添加聚乙烯吡咯烷酮15克溶解於乙 醇11 0克中之溶液並混合則取得懸浮液。將此懸浮液以各 360毫克充填至直徑lOnim之凹型穴中,並於301通風乾燥 後,減壓乾燥1 2小時,取得本發明之速溶性製劑。527195 A7 B7 V. Explanation of the invention (W) Other than pyrrolidone, the same treatment was performed to obtain the preparation of Comparative Example 2. Test Example 4 The same treatment as Test Example 1 was used to measure and measure the hardness and boron time of the preparations of the present invention prepared in Examples 20 to 22 and the preparations of Comparative Examples 1 and 2. The results are summarized in Table 4. (Read the precautions on the back before you fill out this page. Printed by the Ministry of Standards and Standards Bureau Consumer Cooperatives. Table 3: Hardness, disintegration time, and oral dissolution time. Hardness of polyvinylpyrrolidone (Kg). Collapse time (seconds) Adding amount of the examples (%) (average of 10) (average of 6) Example 20 2 1,03 6.0 Example 21 10 2.80 55.0 Example 22 15 5.83 58.0 Comparative Example 1 22 8.24 271.8 Comparative Example 2 0 0,30 1.2 As shown in the results of the table, the preparation of Comparative Example 2 without polyvinylpyrrolidine was very brittle. In addition, the preparation of Comparative Example 1 with a large amount of polyvinylpyrrolidine added collapsed. The soil time is longer than 4 minutes. Relatively, the paper size applies the Chinese National Standard (CNS) Λ4 Regulations (210X297 Gong), -5 mouths. Ju. 527195 Printed by the Shell Standard Consumer Cooperative of the Central Standards Bureau of the Ministry of Lithuania A7五 7 V. Description of the invention (), the preparation of the present invention has hardness and can withstand practical use, and the disintegration time is rapid, which can be understood as a particularly excellent preparation. Za. Tetrafluorosulfan 15 g, sucrose 179,5 G, corn starch 50 g, aspirin 2 grams of sweetness, 0.5 grams of 1-menthol and 2.5 grams of polyvinylpyrrolidone are uniformly mixed. Next, a mixed solution of 105 grams and 45 grams of water is added to this mixed powder and mixed to obtain a suspension. This suspension is 400 mg each Fill it into a concave hole with a diameter of 9βιπ, and dry it at 30t! For 3 hours under ventilation and dry under reduced pressure for 12 hours to obtain the instant soluble preparation of the present invention. The hardness of this preparation is 1.85 kg (average of 10), and it disintegrates. The bad time is 8.3 seconds (average of 6), and the dissolution time in the oral cavity is 37.3 seconds (average of 3 people). Example 2 4 30 g of pyridoxine hydrochloride and 151 g of erythritol , 50g of corn starch, 1g of citric acid, 1g of aspartame, and 2g of spices. Secondly, to this mixed powder, add 15g of polyvinylpyrrolidone to a solution dissolved in 110g of ethanol and mix to obtain Suspension: This suspension was filled into concave cavities with a diameter of 100 nm at 360 mg each, and then dried under aeration in 301 and then dried under reduced pressure for 12 hours to obtain the instant soluble preparation of the present invention.
此製劑於口腔内之溶解時間為1 9 . 7秒(3人之平均值)。 奮J&jajLL 將鹽酸吡哆醇30克、木糖醇151克、玉米澱粉50克、 檸檬酸1克、阿斯巴甜1克及香料2克均勻混合。其次 於此混合粉末中,添加聚乙烯吡咯烷酮1 5克溶解於乙醇 - 26- 本紙張尺度適用中國國家標準(CNS ) Λ4规枱(210X 297公餘 (請先閲讀背面之注意事項再填寫本頁)The dissolution time of this preparation in the oral cavity was 19.7 seconds (average of 3 persons). Fen J & jajLL uniformly mixed 30 g of pyridoxine hydrochloride, 151 g of xylitol, 50 g of corn starch, 1 g of citric acid, 1 g of aspartame and 2 g of spices. Secondly, add 15 grams of polyvinylpyrrolidone to this mixed powder and dissolve it in ethanol-26- This paper size applies Chinese National Standard (CNS) Λ4 gauge (210X 297 public space (please read the precautions on the back before filling this page) )
經滴部中央標準局員工消費合作社印製 527195 A7 R7 五、發明説明(< ) 10 0克中之溶液並混合則取得懸浮液。將此懸浮液以各 350毫克充填至直徑lOinm之凹型穴中,並於30¾通風乾 燥後,減壓乾燥1 5小時,取得本發明之速溶性製劑。 此製劑於口腔内之溶解時間為16秒(3人之平均值)。 C :笛三形熊之谏溶袢因形製_ 鬣 將海藻糖50克溶解於精製水200克中,並於此溶液中 添加四氟硫安定15克、香料5克、阿斯巴甜4.5克及黃 蓍樹驂0. 5克且均勻混合,取得懸浮液。其次,將此懸 浮液以各27 5毫克充填至直徑9min之凹型穴中,冷凍乾燥 ,取得本發明之速溶性製劑。 奮施例27 將海藻耱50克溶解於精製水200克中,並於此溶液中 添加炎痛喜康20克、香料2克、阿斯巴甜5克及瓜阿樹 膠1克且均勻混合,取得懸浮液。其次,將此懸浮液以 各278毫克充填至直徑9ιβιπ之凹型穴中,冷凍乾燥,取得 本發明之速溶性製劑。 奮旃例28 將糊精50克溶解於精製水200克中,並於此溶液中添 加四氟硫安定15克、香料5克、阿斯巴甜4.5克及瓜阿 樹膠0.5克且均勻混合,取得懸浮液。其次,將此懸浮 液以各275毫克充填至直徑9mio之凹型穴中,冷凍乾燥, 取得本發明之速溶性製劑。 奮施例2.i 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210X 297公f ) (請先閲讀背面之注意事項再填寫本頁)Printed by the Consumers' Cooperative of the Central Standards Bureau of the Drop Department 527195 A7 R7 V. Description of the Invention (<) 100 g of the solution and mixed to obtain a suspension. This suspension was filled with 350 mg each into concave cavities with a diameter of 10 inm, and after being air-dried at 30¾, it was dried under reduced pressure for 15 hours to obtain the instant soluble preparation of the present invention. The dissolution time of this preparation in the oral cavity was 16 seconds (average of 3 persons). C: Made of the three-dimensional form of the dilute bear. I dissolve 50 grams of trehalose in 200 grams of purified water, and add 15 grams of tetrafluorosulfanil, 5 grams of spices, and aspartame 4.5 to this solution. Grams and Scutellaria baicalensis 0.5 grams were mixed uniformly to obtain a suspension. Next, this suspension was filled with 275 mg each into concave cavities with a diameter of 9 minutes, and freeze-dried to obtain the instant soluble preparation of the present invention. Fenshi Example 27 Dissolve 50 g of seaweed tincture in 200 g of purified water, and add 20 g of indomethacin, 2 g of spices, 5 g of aspartame, and 1 g of guar gum to this solution, and mix uniformly. Get the suspension. Next, this suspension was filled into concave cavities with a diameter of 9 ιπιπ with 278 mg each, and freeze-dried to obtain the instant soluble preparation of the present invention. Fenzhi Example 28: Dissolve 50 g of dextrin in 200 g of purified water, and add 15 g of tetrafluorothioazepam, 5 g of spices, 4.5 g of aspartame and 0.5 g of guar gum to this solution and mix uniformly. Get the suspension. Next, this suspension was filled into concave cavities with a diameter of 9 mio at 275 mg each, and freeze-dried to obtain the instant soluble preparation of the present invention. Fen Shi Example 2.i This paper size applies to Chinese National Standard (CNS) Λ4 specification (210X 297 male f) (Please read the precautions on the back before filling this page)
527195 經漪部中央標準局員工消費合作社印製 A7 五、發明説明(4 ) 將糊精76克溶解於精製水292克中,並於此溶液中添 加雙氣酚酸鈉25克、檸檬酸10克、香料3克、阿斯巴甜 6克及瓜可樹膠1克且均勻混合,取得懸浮液。其次, 將此懸浮液以各410毫克充填至直徑lOum之凹型穴中, 冷凍乾燥,取得本發明之速溶性製劑。 依據試驗例1同樣之方法,測定實施例26至實施例29 所製造之各製劑的硬度。又,測定崩壞時間及口腔内崩 隳時間。 其結果整理於表5 。 表5:硬度、崩壤時間及口腔内溶解時間 硬度OCg) 崩壤時間(秒) 口腔内溶解時間(秒) 實施例 (10個之平均值) (6個之平均值) (3人之平均值) 實施例26 1.23 10.17 6.0 實施例27 1.12 7.33 5.3 實施例28 1,43 6.17 4·3 實施例29 1,50 4.83 5.3 - 28 - 本紙張尺度適用中國國家標準(CNS ) Λ4規拮(210X297公焓) (誚先閱讀背面之注意事項再填寫本頁)527195 Printed A7 by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the Invention (4) Dissolve 76 g of dextrin in 292 g of purified water, and add 25 g of sodium amphoteric phenol and 10 citric acid to this solution Grams, 3 grams of spices, 6 grams of aspartame, and 1 gram of guaco gum, and evenly mixed to obtain a suspension. Next, this suspension was filled into concave cavities with a diameter of 10 μm at 410 mg each, and freeze-dried to obtain the instant soluble preparation of the present invention. The hardness of each of the preparations produced in Examples 26 to 29 was measured in the same manner as in Test Example 1. In addition, the disintegration time and the intraoral disintegration time were measured. The results are summarized in Table 5. Table 5: Hardness, soil collapse time and oral dissolution time hardness OCg) Soil collapse time (seconds) Oral dissolution time (seconds) Examples (average of 10) (average of 6) (average of 3 persons) Value) Example 26 1.23 10.17 6.0 Example 27 1.12 7.33 5.3 Example 28 1,43 6.17 4 · 3 Example 29 1,50 4.83 5.3-28-This paper size applies the Chinese National Standard (CNS) Λ4 regulation (210X297 (Enthalpy) (诮 Please read the notes on the back before filling this page)
經濟部中央標準局貝工消費合作社印製 527195 A7 五、發明説明(V ) 如表中之結果所蘭明般,本發明之製劑為硬度亦可耐 實用,且崩壤時間亦為10秒以内,再者於口腔内之溶解 時間亦顯示出大約為6秒以内之急速的溶解性,且可理 解其為特別優異之製劑。 産業上之可利用性 如上述,本發明所提供之速溶性固形製劑,因在口腔 内急速溶解,故對呑嚥困難之患者、高齡者、兒童而言 易於服用,且因為卽使無水亦可服用,故藥物可在任何 必須時服用,可期待改善順從性。又,具有可耐實用之 硬度,且吸濕性亦少,故於服用時易於操作,且保管亦 容易,具有通常之操作簡便的優點,於翳療上之可用性 極大。 -29 - 本紙張尺度適用中國國家標準(CNS ) Α4^格(210Χ297公錄) (謂先閲讀背面之注意事項再填寫本頁)Printed by the Central Standards Bureau of the Ministry of Economic Affairs, Shellfish Consumer Cooperative, 527195 A7 V. Description of the invention (V) As the results in the table show, the preparation of the present invention has hardness and can withstand practical use, and the soil collapse time is within 10 seconds. In addition, the dissolution time in the oral cavity also shows rapid solubility within about 6 seconds, and it can be understood that it is a particularly excellent preparation. The industrial applicability is as described above. The fast-dissolving solid preparation provided by the present invention is rapidly dissolved in the oral cavity, so it is easy to take for patients, elderly people, and children who have difficulty with pharyngeal pharynx. It can be taken whenever necessary, and it is expected to improve compliance. In addition, it has practical hardness and low hygroscopicity, so it is easy to handle when taking it, and easy to store. It has the advantages of simple and convenient operation, and has great usability in medical treatment. -29-This paper size applies to China National Standard (CNS) Α4 ^ Grid (210 × 297) (It is said that you must read the precautions on the back before filling in this page)
Claims (1)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29184397A JPH11116466A (en) | 1997-10-09 | 1997-10-09 | Rapid dissolution type solid preparation and method for producing the same |
JP29184197A JPH11116464A (en) | 1997-10-09 | 1997-10-09 | Fast dissolving solid preparation and method for producing the same |
JP29184297A JPH11116465A (en) | 1997-10-09 | 1997-10-09 | Rapid dissolving preparation and method for producing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
TW527195B true TW527195B (en) | 2003-04-11 |
Family
ID=27337696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW087116540A TW527195B (en) | 1997-10-09 | 1998-10-06 | Fast-soluble solid pharmaceutical combinations |
Country Status (7)
Country | Link |
---|---|
US (1) | US6455053B1 (en) |
EP (1) | EP1022021A1 (en) |
KR (1) | KR20010024464A (en) |
CN (1) | CN1281356A (en) |
CA (1) | CA2305756A1 (en) |
TW (1) | TW527195B (en) |
WO (1) | WO1999018936A1 (en) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100693266B1 (en) | 1997-03-28 | 2007-03-27 | 에자이 가부시키가이샤 | Oral medicine that hides bitter taste |
JP4748627B2 (en) * | 1998-07-15 | 2011-08-17 | 旭化成ケミカルズ株式会社 | Excipient |
KR100801236B1 (en) * | 1998-08-28 | 2008-02-11 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Pharmaceutical composition which reduced bitterness |
KR20100008007A (en) * | 1999-02-15 | 2010-01-22 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | Tablets quickly disintegrated in the oral cavity |
GB9904049D0 (en) * | 1999-02-22 | 1999-04-14 | Quadrant Holdings Cambridge | Rapidly-soluble compositions |
US8758400B2 (en) | 2000-01-05 | 2014-06-24 | Integrated Vascular Systems, Inc. | Closure system and methods of use |
US9579091B2 (en) | 2000-01-05 | 2017-02-28 | Integrated Vascular Systems, Inc. | Closure system and methods of use |
US6391048B1 (en) | 2000-01-05 | 2002-05-21 | Integrated Vascular Systems, Inc. | Integrated vascular device with puncture site closure component and sealant and methods of use |
ES2327898T3 (en) * | 2000-03-01 | 2009-11-05 | EISAI R&D MANAGEMENT CO., LTD. | RAPID DISINTEGRATION TABLET CONTAINING POLI (VINYL ALCOHOL). |
JP4711520B2 (en) * | 2000-03-21 | 2011-06-29 | 日本ケミカルリサーチ株式会社 | Bioactive peptide-containing powder |
CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
CA2421950A1 (en) | 2000-09-08 | 2002-03-14 | James E. Coleman | Surgical staple |
US6626918B1 (en) | 2000-10-06 | 2003-09-30 | Medical Technology Group | Apparatus and methods for positioning a vascular sheath |
JP4446463B2 (en) * | 2000-10-16 | 2010-04-07 | 第一三共株式会社 | Oral rapidly disintegrating pharmaceutical composition and method for producing the same |
US6623510B2 (en) | 2000-12-07 | 2003-09-23 | Integrated Vascular Systems, Inc. | Closure device and methods for making and using them |
US6695867B2 (en) | 2002-02-21 | 2004-02-24 | Integrated Vascular Systems, Inc. | Plunger apparatus and methods for delivering a closure device |
US8690910B2 (en) | 2000-12-07 | 2014-04-08 | Integrated Vascular Systems, Inc. | Closure device and methods for making and using them |
US7905900B2 (en) | 2003-01-30 | 2011-03-15 | Integrated Vascular Systems, Inc. | Clip applier and methods of use |
ES2268020T3 (en) * | 2001-05-10 | 2007-03-16 | Astellas Pharma Inc. | FAST DISGREGATION TABLES OF ORAL CAVITY AND PROCESS TO PRODUCE THE SAME. |
US6872405B2 (en) | 2001-05-10 | 2005-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Quick-disintegrating tablet in buccal cavity and manufacturing method thereof |
US20040137061A1 (en) * | 2001-06-07 | 2004-07-15 | Takashi Ishibashi | Functional grain-containing preparations quickly disintegrated in the oral cavity |
AU2003238642A1 (en) | 2002-06-04 | 2003-12-19 | Christy Cummins | Blood vessel closure clip and delivery device |
EP1585502B9 (en) * | 2002-11-12 | 2012-05-09 | Elan Pharma International Limited | Fast-disintegrating solid dosage forms being not friable and comprising pullulan |
US8202293B2 (en) | 2003-01-30 | 2012-06-19 | Integrated Vascular Systems, Inc. | Clip applier and methods of use |
US8905937B2 (en) | 2009-02-26 | 2014-12-09 | Integrated Vascular Systems, Inc. | Methods and apparatus for locating a surface of a body lumen |
US8398656B2 (en) | 2003-01-30 | 2013-03-19 | Integrated Vascular Systems, Inc. | Clip applier and methods of use |
US20070059358A1 (en) * | 2003-07-02 | 2007-03-15 | Tianjin Tasly Pharmaceutical Co., Ltd., China | Matrix adjuvants and the drop pills prepared with them |
MX2007007885A (en) * | 2004-12-23 | 2007-10-04 | Johnson & Johnson | Orally disintegrating pharmaceutical compositions with sensory cue agents. |
US8926633B2 (en) | 2005-06-24 | 2015-01-06 | Abbott Laboratories | Apparatus and method for delivering a closure element |
US8313497B2 (en) | 2005-07-01 | 2012-11-20 | Abbott Laboratories | Clip applier and methods of use |
WO2007026755A1 (en) * | 2005-08-31 | 2007-03-08 | Ezaki Glico Co., Ltd. | Tablet for removal of tongue coating |
US8556930B2 (en) | 2006-06-28 | 2013-10-15 | Abbott Laboratories | Vessel closure device |
KR101435229B1 (en) * | 2006-09-14 | 2014-08-28 | 아스테라스 세이야쿠 가부시키가이샤 | Oral disintegrating tablets and their preparation |
US20100093875A1 (en) * | 2006-10-25 | 2010-04-15 | Dainippon Sumitomo Pharma Co., Ltd. | Granular preparation prevented from caking |
US8893947B2 (en) | 2007-12-17 | 2014-11-25 | Abbott Laboratories | Clip applier and methods of use |
EP2233129B1 (en) * | 2007-12-28 | 2014-05-07 | Sawai Pharmaceutical Co., Ltd. | Oral cavity disintegrating tablet and method of producing the same |
US9282965B2 (en) | 2008-05-16 | 2016-03-15 | Abbott Laboratories | Apparatus and methods for engaging tissue |
FR2933299B1 (en) * | 2008-07-04 | 2012-02-03 | Roquette Freres | MANNITOL ORODISPERSIBLE |
US8398676B2 (en) | 2008-10-30 | 2013-03-19 | Abbott Vascular Inc. | Closure device |
US8858594B2 (en) | 2008-12-22 | 2014-10-14 | Abbott Laboratories | Curved closure device |
US9414820B2 (en) | 2009-01-09 | 2016-08-16 | Abbott Vascular Inc. | Closure devices, systems, and methods |
US20100179589A1 (en) | 2009-01-09 | 2010-07-15 | Abbott Vascular Inc. | Rapidly eroding anchor |
US9173644B2 (en) | 2009-01-09 | 2015-11-03 | Abbott Vascular Inc. | Closure devices, systems, and methods |
US9089311B2 (en) | 2009-01-09 | 2015-07-28 | Abbott Vascular Inc. | Vessel closure devices and methods |
US9486191B2 (en) | 2009-01-09 | 2016-11-08 | Abbott Vascular, Inc. | Closure devices |
US20100185234A1 (en) | 2009-01-16 | 2010-07-22 | Abbott Vascular Inc. | Closure devices, systems, and methods |
WO2010086989A1 (en) | 2009-01-29 | 2010-08-05 | 日東電工株式会社 | Intraoral film-shaped base and preparation |
US20110054492A1 (en) | 2009-08-26 | 2011-03-03 | Abbott Laboratories | Medical device for repairing a fistula |
JP5751868B2 (en) * | 2010-03-30 | 2015-07-22 | 日東電工株式会社 | Film-form preparation and method for producing the same |
US9332976B2 (en) | 2011-11-30 | 2016-05-10 | Abbott Cardiovascular Systems, Inc. | Tissue closure device |
JP5841433B2 (en) | 2012-01-11 | 2016-01-13 | 日東電工株式会社 | Intraoral film-form base and preparation |
JP6195848B2 (en) | 2012-01-27 | 2017-09-13 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニアThe Regents Of The University Of California | Stabilization of biomolecules using sugar polymers |
US9364209B2 (en) | 2012-12-21 | 2016-06-14 | Abbott Cardiovascular Systems, Inc. | Articulating suturing device |
US10994013B2 (en) | 2013-04-24 | 2021-05-04 | Temple University—Of the Commonwealth System of Higher Education | Solid dosage form containing arabinogalactan |
JP6574556B2 (en) * | 2014-08-27 | 2019-09-11 | 日東電工株式会社 | Intraoral film-form base and preparation |
CN107206098B (en) * | 2015-02-12 | 2021-06-01 | 株式会社盛本医药 | Jelly for assisting administration of drug and method for producing the same |
CN109068709B (en) * | 2017-07-07 | 2022-07-22 | 江西清源汉本生物科技有限公司 | Instant product and process for its preparation |
WO2019007138A1 (en) * | 2017-07-07 | 2019-01-10 | 江西清源汉本生物科技有限公司 | Instant product and preparation method therefor |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE45770B1 (en) | 1976-10-06 | 1982-11-17 | Wyeth John & Brother Ltd | Pharmaceutical dosage forms |
US4327080A (en) | 1981-07-13 | 1982-04-27 | E. R. Squibb & Sons, Inc. | Novel Bendroflumethiazide formulations and method |
DE3142853A1 (en) | 1981-10-29 | 1983-05-11 | Bayer Ag, 5090 Leverkusen | Solid pharmaceutical compositions containing nifedipine and process for their production |
EP0078430B2 (en) | 1981-10-29 | 1993-02-10 | Bayer Ag | Process for preparing solid fast-releasing drug formulations of dihydropyridines |
ATE24964T1 (en) | 1981-12-11 | 1987-01-15 | Wyeth John & Brother Ltd | PROCESS FOR THE MANUFACTURE OF SOLID MOLDED OBJECTS. |
JPS58194808A (en) | 1982-05-10 | 1983-11-12 | ナビスコ・ブランズ・インコ−ポレイテツド | Compress mastication tablet and manufacture |
EP0345628B1 (en) | 1988-06-07 | 1993-05-12 | Abbott Laboratories | Solid pharmaceutical dosage in tablet triturate form and method of producing same |
FR2647343B1 (en) | 1989-05-24 | 1994-05-06 | Rhone Poulenc Sante | NOVEL POROUS PHARMACEUTICAL FORM AND ITS PREPARATION |
US5039540A (en) | 1989-08-14 | 1991-08-13 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
US5079018A (en) | 1989-08-14 | 1992-01-07 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
JP2845342B2 (en) | 1990-04-28 | 1999-01-13 | 大正製薬株式会社 | Vitamin D Lower 3 Derivative-Containing Solid Preparation Composition |
WO1992021328A1 (en) * | 1991-05-28 | 1992-12-10 | Affinity Biotech, Inc. | Chewable drug-delivery composition |
US5464632C1 (en) | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
FR2679451B1 (en) * | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | MULTIPARTICLE TABLET WITH RAPID DELIVERY. |
KR100256147B1 (en) * | 1991-12-24 | 2000-08-01 | 오노다 마사요시 | Oral disintegrating preparations and preparation method thereof |
EP0553777B1 (en) | 1992-01-29 | 2002-04-24 | Takeda Chemical Industries, Ltd. | Fast dissolving tablet and its production |
JPH05310558A (en) | 1992-05-07 | 1993-11-22 | Lion Corp | Solid preparation composition |
JP3063438B2 (en) | 1992-12-24 | 2000-07-12 | 田辺製薬株式会社 | Dopamine derivative-containing formulation for oral administration |
DE69429119T2 (en) | 1993-07-09 | 2002-07-18 | R.P. Scherer Corp., Troy | METHOD FOR PRODUCING FREEZER DRIED DRUG DOSAGE FORMS |
CA2128820A1 (en) * | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
US5576014A (en) * | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
JP2705787B2 (en) | 1994-09-30 | 1998-01-28 | 山之内製薬株式会社 | Easy to take bitterness improving H 改善 2H blocker solid preparation |
JP3067125B2 (en) | 1994-11-22 | 2000-07-17 | 田辺製薬株式会社 | Easy-to-take nucleated tablet-type preparation |
DE4444052A1 (en) | 1994-12-10 | 1996-06-13 | Rhone Poulenc Rorer Gmbh | Pharmaceutical, oral preparation |
DE4444051A1 (en) | 1994-12-10 | 1996-06-13 | Rhone Poulenc Rorer Gmbh | Pharmaceutical, oral preparation |
JP3418274B2 (en) | 1995-06-05 | 2003-06-16 | 日本化薬株式会社 | Tablets with good oral feel |
JPH0948726A (en) | 1995-08-07 | 1997-02-18 | Tanabe Seiyaku Co Ltd | Orally rapidly disintegrating preparation and method for producing the same |
JPH0971523A (en) * | 1995-09-07 | 1997-03-18 | Riyuukakusan:Kk | Tablet quickly disintegrating in oral cavity |
US5980941A (en) * | 1997-08-20 | 1999-11-09 | Fuisz Technologies Ltd. | Self-binding shearform compositions |
-
1998
- 1998-10-06 TW TW087116540A patent/TW527195B/en active
- 1998-10-07 CN CN98812014A patent/CN1281356A/en active Pending
- 1998-10-07 KR KR1020007003808A patent/KR20010024464A/en not_active Withdrawn
- 1998-10-07 CA CA002305756A patent/CA2305756A1/en not_active Abandoned
- 1998-10-07 EP EP98947768A patent/EP1022021A1/en not_active Withdrawn
- 1998-10-07 WO PCT/JP1998/004526 patent/WO1999018936A1/en not_active Application Discontinuation
- 1998-10-07 US US09/509,988 patent/US6455053B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20010024464A (en) | 2001-03-26 |
US6455053B1 (en) | 2002-09-24 |
CA2305756A1 (en) | 1999-04-22 |
EP1022021A1 (en) | 2000-07-26 |
WO1999018936A1 (en) | 1999-04-22 |
CN1281356A (en) | 2001-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW527195B (en) | Fast-soluble solid pharmaceutical combinations | |
EP1674083B1 (en) | Tablet quickly disintegrating in oral cavity | |
TW391880B (en) | An oral soluble type compression moulding and its preparation | |
TW404840B (en) | Fluoxetine pharmaceutical formulations | |
EP1523974B1 (en) | Composition for rapid disintegrating tablet in oral cavity | |
TWI257311B (en) | Rapidly disintegrable solid preparation | |
JP2002179558A (en) | Solid preparation | |
WO2013123623A1 (en) | Oroally disintegrating tablet and preparation method therefor | |
JP3900245B2 (en) | Intraoral rapidly disintegrating tablet and method for producing the same | |
CN102846581A (en) | Ambroxol hydrochloride oral fast-dissolving film and preparation method thereof | |
CN101209249A (en) | Spaston orally disintegrating tablets and preparation thereof | |
TWI714536B (en) | Disintegrable particle composition containing crushed lactose or granulated lactose | |
CN107095853A (en) | A kind of oral disnitegration tablet disintegrant combination and its application method | |
CN107789328A (en) | A kind of oral disintegrating tablet containing Doneppezil Hydrochloride and preparation method thereof | |
CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
Nasreen et al. | Mouth dissolving tablets-A unique dosage form curtailed for special purpose: a review | |
CN102309460B (en) | Pyridostigmine bromide odor masking orally disintegrating tablets and preparation method thereof | |
CN1856298B (en) | Tablet quickly disintegrating in oral cavity | |
JPH11116465A (en) | Rapid dissolving preparation and method for producing the same | |
CN102247331B (en) | Cefadroxil chewable tablets and preparation method thereof | |
JPH11116464A (en) | Fast dissolving solid preparation and method for producing the same | |
CN100490816C (en) | Azithromycin orally disintegrating tablet and preparation method thereof | |
Tat et al. | A REVIEW ON UTILIZATION OF NATURAL SUPERDISINTEGRANT IN THE ADVANCEMENT OF ORALLY DISPERSIBLE TABLET | |
JPH11116466A (en) | Rapid dissolution type solid preparation and method for producing the same | |
TW200944250A (en) | Oral solid composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent |